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Introduction
Sustained ventricular arrhythmias—ventricular tachycar-
dia (VT) and ventricular fibrillation (VF)—are important
causes of morbidity and sudden death (SD), especially in
patients with structural heart disease. Therapeutic options
for the treatment of these arrhythmias include antiarrhyth-
mic drugs, implantable cardioverter-defibrillators (ICDs),
and surgical and catheter ablation. Antiarrhythmic drugs have
disappointing efficacy and adverse side effects that may out-
weigh benefits. ICDs effectively terminate VT/VF episodes
and represent the mainstay therapy to prevent SD. However,
ICD shocks are painful, reduce quality of life, and predict
increased risk of death and heart failure.
Catheter ablation, as therapeutic option for ventricular
arrhythmias, was first proposed in 1983.1 Since then, sig-
nificant developments in ablation and mapping technolo-
gies have been made. The most relevant developments
include the use of radiofrequency (RF) energy, introduc-
tion of steerable, large-tip, and irrigated catheters, activation
and entrainment mapping, electroanatomic mapping with the
possibility of performing substrate-based ablation during si-
nus rhythm, multielectrode mapping with the possibility of
ablating hemodynamically unstable VT, and epicardial map-
ping and ablation. All these advances have contributed to
improved outcomes and to a substantial expansion in the
indications of catheter ablation of ventricular arrhythmias.
Moreover, they have generated the need to standardize the
different aspects of the procedure.
Inspired by this need, the Organizers of Venice Arrhyth-
mias 2009 assembled world-recognized experts in the field
of ventricular arrhythmias to develop an international con-
sensus document on VT/VF ablation. In this article, the work
produced by this group of experts is reported.
Definition, Classification, and Clinical
Presentation of VT/VF
Definition
Ventricular arrhythmias are defined as arrhythmias that
originate below the bifurcation of His bundle, in the special-
ized conduction system, the ventricular muscle, or in combi-
nation of both tissues.
There are different classifications of ventricular arrhyth-
mias, according to their duration, morphology of QRS com-
plexes, and clinical characteristics.
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Classification According to Duration
(1) Premature ventricular complexes (PVC): isolated com-
plexes originating from the His-Purkinje system or ven-
tricular myocardium.
(2) VT: 3 or more consecutive QRS complexes at a rate
greater than 100 beats per minute.
(3) Nonsustained VT: VT that terminates spontaneously
within 30 seconds.
(4) Sustained VT: continuous VT lasting for ≥30 seconds
or that requires an intervention for termination (such as
cardioversion).
Classification According to Morphology of QRS
Complexes
(1) Monomorphic VT: VT that has a similar QRS configu-
ration from beat to beat. Some variability in QRS mor-
phology at initiation is not uncommon.
(2) Multiple monomorphic VT: more than one morpholog-
ically distinct monomorphic VT, occurring as different
episodes or induced at different times.
(3) Polymorphic VT: VT that has a continuously changing
QRS configuration indicating a changing ventricular ac-
tivation sequence.
(4) Pleomorphic VT: VT that has more than one morpholog-
ically distinct QRS complex occurring during the same
episode of VT, but the QRS is not continuously chang-
ing.
(5) Ventricular flutter: rapid VT that has a sinusoidal QRS
configuration that prevents identification of the QRS
morphology.
(6) VF: ventricular tachyarrhythmia that has a totally chaotic
morphology.
Classification According to Clinical Characteristics
(1) Clinical VT: VT that has occurred spontaneously based
on analysis of 12-lead ECG QRS morphology and rate.
(2) Hemodynamically unstable VT: VT that causes hemo-
dynamic compromise requiring prompt termination.
(3) Incessant VT: continuous sustained VT that recurs im-
mediately despite repeated spontaneous or therapeutic
termination.
(4) Repetitive monomorphic VT: continuously repeating
episodes of self terminating nonsustained VT.
(5) VT storm: 3 or more separate episodes of sustained VT
within 24 hours, each requiring termination by an inter-
vention.
(6) Unmappable VT: VT that does not allow interrogation
of multiple sites to define the activation sequence or
perform entrainment mapping. It may be due to hemo-
dynamic intolerance that necessitates immediate VT ter-
mination, spontaneous, or pacing-induced transition to
other morphologies of VT, or repeated termination dur-
ing mapping.
VT/VF Clinical Presentation
Coronary heart disease is the most frequent cause of clin-
ically documented VT and VF (76–82% of the patients).2-5
Other common causes of ventricular arrhythmias are non-
ischemic dilated cardiomyopathy (DCM), hypertrophic car-
diomyopathy (HCM), arrhythmogenic right ventricular car-
diomyopathy (ARVC), congenital heart disease, especially
tetralogy of Fallot, aortic stenosis, transposition of the great
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arteries, and hereditary arrhythmogenic syndromes, such as
long QT syndrome (LQTS), short QT syndrome (SQTS),
Brugada syndrome, and catecholaminergic polymorphic ven-
tricular tachycardia (CPVT). In a limited number of patients
with VT/VF (≈5%) no documented structural cardiac abnor-
malities can be identified.
Symptoms that occur during VT are highly variable and
greatly depend upon the rate and the duration of the VT,
and the extent of the concomitant underlying heart disease.
According to the presence and intensity of hemodynamic
compromise and symptoms, VT may be defined, from a clin-
ical point of view, as hemodynamically stable and hemo-
dynamically unstable. Hemodynamically stable VTs do not
cause symptoms or are only associated with palpitations.
Hemodynamically unstable VTs are responsible of severe
symptoms, such as dyspnea, chest pain, lightheadedness,
presyncope, and syncope. However, symptoms alone do not
identify a cardiac rhythm as being due to VT. Moreover, the
cumulative survival of each symptomatic subgroup of pa-
tients with VT is surprisingly similar and is approximately
70% at 3 years.6 Sustained VT/VF are the usual cause of SD
in the general population, reported to occur with an incidence
of 0.1% to 0.2% per year.7
Anatomy of Right/Left Ventricles and Surrounding
Structures
Catheter ablation of VT is a highly complex procedure
that requires both advanced knowledge in the techniques
of electrophysiologic mapping and also an in-depth under-
standing of the anatomy of the ventricles, the aortic root, and
surrounding structures.
Normal Anatomy of Right and Left Ventricles
Disposition of the ventricular chambers and great arteries
The intricate spatial relationship between right and left
ventricles reflects the anatomical fact that right ventricle,
being the most anteriorly situated cardiac chamber, overlaps
the left ventricle. In addition, the shapes of the left and right
ventricles are dissimilar and the ventricular septum is not
straight but curved. The inflow and outflow tracts of the left
ventricle overlap each other when viewed from the frontal
aspect whereas they are well separated in the right ventricle.
Particularly relevant to ablations in the outflow tracts is,
to understand the “crossover” relationship between the right
and left ventricular outlets. The right ventricular outlet passes
cephalad in a posterior and slightly leftward direction. The
left ventricular outlet passes underneath the right ventricular
outlet in a rightward and cephalad direction, pointing toward
the right shoulder. Furthermore, the pulmonary and aortic
valves are not at the same level. The pulmonary valve is the
most superiorly situated of the cardiac valves, whereas the
aortic valve slopes inferiorly at an angle to the pulmonary
valve.8 The difference in levels between the 2 sets of arterial
valves may be exaggerated by the length of the free-standing
cone of muscle supporting the pulmonary valve known as the
subpulmonary infundibulum (Fig. 1A,B).
Right ventricle
The posteroinferior wall of the subpulmonary infundibu-
lum overlies the anterior walls of the left and right coronary
sinuses to a greater or lesser extent and may give the im-
pression of myocardial sleeves covering the aortic sinuses.
In the sinuses nearest to the infundibulum are the orifices of
the right and left coronary arteries.9,10 As the coronary arter-
ies descend toward their respective atrioventricular grooves,
they pass within millimeters of the epicardial aspect of the
infundibulum.11
A muscular fold known as the ventriculo-infundibular fold
separates the tricuspid from pulmonary valves (Fig. 1A). On
its epicardial aspect sits the right coronary sinus of the aortic
root. The fold continues superiorly into the muscle of the sub-
pulmonary infundibulum that adjoins the arterial wall of the
pulmonary trunk at the ventriculo-arterial junction (Fig. 1B).
The pulmonary sinuses are not as prominent as the aortic
sinuses; there is a small segment of infundibular muscula-
ture at the nadirs of each sinus.12 Distinctive of the septal
surface of the right ventricle is a Y-shaped muscle band,
the septomarginal trabeculation. The ventriculo-infundibular
fold arises from between the limbs of the Y to form the
supraventricular crest. The attachment of the medial papil-
lary muscle to the inferior limb is the landmark for the right
bundle branch that emerges from its transseptal course onto
the subendocardium (Fig. 1A). The moderator band arising
from the body of the septomarginal trabeculation carries a
fascicle of the right bundle branch to the parietal wall of the
right ventricle. The apical portion of the right ventricle is
characterized by a meshwork of coarse muscular trabecula-
tions. The ventricular wall in between the trabeculations is
about 2 mm thick.
Left ventricle
The central location of the aortic valve in the heart places
the outflow tract in between the mitral valve and the ventric-
ular septum (Fig. 1C). The septal half of the aortic outlet is
muscular, whereas the other half is an area of fibrous conti-
nuity between mitral and aortic valves. The curvature of the
ventricular septum continuing into the free wall forms the
anterosuperior wall of the left ventricular outflow tract. The
semilunar hingelines of the aortic leaflets enclose a segment
of ventricular myocardium in the nadir of the right coronary
aortic sinus and the adjacent part of the left coronary aortic
sinus (Fig. 1C). The interleaflet fibrous triangles between ad-
jacent sinuses project like the prongs of a coronet above the
ventricular chamber. The triangle between right and noncoro-
nary leaflets proximally is continuous with the membranous
septum making it a landmark for the atrioventricular con-
duction bundle that emerges in the left ventricle positioned
between the membranous septum and muscular ventricular
septum (Fig. 1C). The left bundle branch descends in the
subendocardium of the muscular septum and fans into 3 in-
terconnecting main fascicles that ramify distally into fine
strands. Some strands may be carried within so-called false
tendons. The left ventricle is characterized by fine apical tra-
beculations and thick muscular walls. However, the wall is
thin at the very apex.
Arrhythmogenic Substrate of VT/VF
VT and VF are usually initiated by mechanisms of reen-
try in the ventricular myocardium. Reentry depends on the
coexistence of an arrhythmogenic substrate, which is a pre-
existent structural pathological condition in the heart, and a
“trigger,” such as acute ischemia that initiates the electrical
abnormality. Infarcts often show marked spatial heterogene-
ity, with areas of necrosis interspersed with bundles of viable
myocytes, particularly at the periphery of the infarct and,
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Figure 1. (A) and (B) are dissections
into the right ventricle and into the right
ventricular outflow tract (white arrow).
(A) The ventriculo-infundibular fold (v)
continues into the muscle of the subpul-
monary infundibulum that surrounds the
outflow tract (arrow). Y marks the sep-
tomarginal trabeculation. The moderator
band (black arrow) arises from its body
while the medial papillarty muscle (as-
terisk) inserts into its inferior limb. (B)
This deeper cut profiles the right ventric-
ular outflow tract to show the muscular
infundibulum leading to the pulmonary
valve at the ventriculoarterial junction
(triangle). The oval marks the area of
the central fibrous body. (C) This longi-
tudinal section shows the right ventric-
ular outflow tract (RVOT) passing over
the aortic outflow tract. The musculature
of the RVOT (small white arrows) overly-
ing the aortic sinuses and the ascending
aorta can give the impression of there be-
ing an extensive muscular sleeve around
the aorta. The triangle indicates the pres-
ence of muscle at the nadir of the right
coronary aortic sinus (r). The location of
the atrioventricular conduction bundle is
depicted by asterisks. LA = left atrium;
LV= left ventricle; n= noncoronary aor-
tic sinus; STJ = sinutubular junction.
in the reparative phase, this may lead to formation of fibro-
cellular, fibrosclerotic, or fibroadipose scars with irregular
outlines. Heterogeneity in tissue composition and autonomic
innervations in these regions may create areas of aberrant
conduction that generate the substrate for lethal reentrant ar-
rhythmias.13 The pathologic hallmark of ARVC is myocyte
loss with fibrofatty replacement. In HCM, the histopatho-
logical hallmarks are myocyte hypertrophy, disarray, and
interstitial fibrosis. In DCM, the histological changes are
mostly nonspecific and include myocyte attenuation, exten-
sive myofibrillary loss with vacuolated appearance and perin-
uclear halo, dysmorphic and dysmetric nuclei, and interstitial
fibrosis. Isolated left ventricular noncompaction is thought
to be the consequence of the postnatal persistence of the
embryonic pattern of myocyte architecture. Pathologically,
the noncompacted layer of the myocardium consists of ex-
cessively prominent trabeculations with deep intertrabecular
recesses extending into the compacted myocardial layer. In
myocarditis, VT and VF may develop in the setting of un-
stable myocardial substrate, namely inflammatory infiltrate,
interstitial edema, myocardial necrosis, and fibrosis.
Important Structures Near the Heart
Pericardium
The heart and the adjacent parts of the great arteries and
veins are enclosed by pericardium consisting of 2 compo-
nents: the fibrous and the serous pericardium. The fibrous
pericardium is a sac made of tough connective tissue that
completely surrounds the heart and is attached only at its
arterial and venous poles. The serous pericardium consists
of 2 layers of serous membrane. The inner (visceral) layer
forms the epicardium of the heart, whereas the outer (pari-
etal) layer is adherent to the internal surface of the fibrous
pericardium.14,15 The visceral layer is reflected from the heart
and the great vessels to continue into the parietal layer thus
enclosing between the layers a narrow space, the pericar-
dial cavity, which is filled normally with 20–25 cc of serous
fluid.
The pericardial space can be accessed via a subx-
iphoid puncture and it allows relatively free manipulation of
catheters around the epicardial surface of the heart, especially
the ventricles, except in cases with pericardial adhesions.
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Phrenic nerves
The phrenic nerves accompanied by the pericardiophrenic
vessels descend bilaterally onto the pericardium. The right
phrenic nerve has a close anatomic relationship with the supe-
rior caval vein (minimal distance 0.3± 0.5 mm) and the right
superior pulmonary vein (minimal distance 2.1± 0.4 mm) as
it runs through the lateral and posterolateral wall of the right
atrium.16,17 The left phrenic nerve descends either anteriorly
or anterolaterally over the area of the left ventricle to insert
in the diaphragm behind the cardiac apex.17
Pathophysiology and Mechanisms of VT/VF
Electrophysiological Abnormalities
Responsible for VT/VF
VT/VF may be caused by different electrogenetic mecha-
nisms. They include abnormal automaticity, triggered activ-
ity, and single or multiple reentry. The cause of normal auto-
maticity in subsidiary pacemakers (especially His-Purkinje
fibers) is a spontaneous decline in the membrane potential
during diastole, the pacemaker potential, that is, under auto-
nomic control. When resting potentials are reduced, sponta-
neous diastolic depolarization may occur and cause repeti-
tive impulse initiation by abnormal automaticity.18 Triggered
activity is dependent on afterdepolarizations. Delayed after-
depolarizations are caused by an increase in intracellular
Ca2+ (“Ca overload”).19 Early afterdepolarizations are as-
sociated with prolongation of action potential duration and
cause triggered torsades de pointe.20 Reentry is dependent on
unidirectional conduction block and an impulse wavelength
(conduction velocity× refractory period) that is shorter than
the path length of the reentrant circuit.
Pathophysiology and Mechanisms of VF
Experimental data support the hypothesis that VF is a
result of many spiraliform waves reentry in the ventricular
myocardium.21,22 This chaotic arrhythmia is a final result
of several pathogenetic expressions. To start VF, different
factors are necessary, in particular (1) triggers (for example,
single PVC, PVC runs, and VT) and (2) the occurrence of
complex neuroendocrine interactions, electrolyte changes,
hypoxia, inflammation, drugs, mechanical factors, among
many others.7 The most frequent cause of VF is acute my-
ocardial ischemia. It provokes serious electrical instability,
with enhanced automaticity, shortening, and different du-
ration of cell action potentials (AP) in the area of ischemic
tissue. In ischemic cardiomyopathy, other factors besides my-
ocardial ischemia play a role. The zone bordering the scar
area, where live tissue coexists with fibrotic tissue, is often
the structural substrate in which ventricular arrhythmias are
produced.23 In this area there is a wide variability of the AP
duration, so that it is the basis of the reentry and electri-
cal instability. Recent studies have shown that His-Purkinje
fibers may be involved in the genesis of early-onset PVC,
which can trigger VT or VF.24 The risk of developing malig-
nant ventricular arrhythmias increases in patients with heart
failure and left ventricular ejection fraction (EF) <40%.25
This has been observed also in nonischemic cardiomyopa-
thy. Idiopathic VF occurs in about 5–10% of survivors of
out-hospital cardiac arrest.26 Recent attention has focused
on the inherited aspects of ion channelopathies in these pa-
tients. Spatial electrical heterogeneity within the ventricular
myocardium through different changes of diastolic potential
genetically determined in LQTS,27 SQTS and Brugada syn-
drome,28 as well as CPVT, explains high electrical instability
in these patients.29 VF occurs when these alterations in de-
polarization are stressed by physical, emotional, metabolic,
or drug-related factors. Genetic defects can also contribute
to drug-induced channelopathies. Polymorphic genetic alter-
ations in apparently normal patients cause an exaggerated
drug action.
Pathophysiology and Mechanisms of VT
VT in structural heart disease
Sustained monomorphic VT is often the clinical mani-
festation of an underlying structural heart disease.7,30 VT
that occurs in this setting most frequently appears to be re-
lated to reentry arising from a stable substrate. Fibrosis or
fibrofatty replacement of ventricular myocardium create scar
regions that are regarded as the arrhythmogenic disease sub-
strate.31 Morphologic studies consistently demonstrate that
the myocardial lesion responsible for VT is characterized
by islands of surviving ventricular myocardium embedded
into scar tissue.30,31 This inhomogeneous histopathologic
arrangement accounts for nonuniform intraventricular con-
duction in the surviving but electrophysiologically abnormal
myocardial tissue, with slow regional activation and areas of
functional block that promote reentrant excitation (reentrant
circuits with a “figure of eight” pattern)32 Fig. 2).
Old myocardial infarction is the most common source of
ventricular scar that gives rise to monomorphic left VT.33
In HCM, microreentry circuits related to intraseptal small
scar areas produce rapid monomorphic/polymorphic VT that
tends to degenerate into VF and SD.34 Sustained monomor-
phic VT is also observed in DCM. The underlying mecha-
nism is usually a scar-related reentry circuit predominantly
located close to the valve annulus, although a bundle branch
reentry or phase 4-dependent enhanced automaticity may
be occasionally involved.7,35 Scar-related right VT (with a
left bundle branch block morphology) may occur in patients
with ARVC and cardiac sarcoidosis.36-39 Reentry circuits
often develop around scars or aneurysms in the subtricus-
pidal, apical, or infundibular regions (“triangle of dyspla-
sia”). Multiple VTs are commonly observed and suggest
a widespread fibrofatty myocardial replacement resulting
in multifocal arrhythmogenic scar regions. In tetralogy of
Fallot, postexcisional myocardial fibrosis and/or synthetic
patches used to close the septal defect and reconstruct the
pulmonary infundibulum act as a substrate for the VT reentry
circuit.40
Idiopathic VT
Idiopathic VT is classified into several categories, (1)
verapamil-sensitive left VT or fascicular VT;41,42 (2) out-
flow VT;43,44 (3) inflow VT of mitral and tricuspid valve
annulus origin; (4) left VT of papillary muscle origin;45
and (5) epicardial VT arising from close proximity to
the coronary venous system including the anterior inter-
ventricular vein, the distal great cardiac vein, the anterior
interventricular vein-great cardiac vein junction.46 The
mechanism of typical verapamil-sensitive left VT is well
demonstrated to be macroreentry involving the Purkinje sys-
tem at the left posterior fascicular area with the estimated dis-
tance of approximately 2 cm between its entrance and exit.
Rarely, there is left anterior fascicle VT with right bundle
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Figure 2. Panel A shows histologic view of the infarcted tissue in the inferoapical wall of the left ventricle (LV), as indicated by the schematic representation
of the heart on the right upper corner. Bundles of surviving myocardium are seen (in black) connecting the 2 borders of scar (in white) at different levels.
Panel B shows a 3-dimensional model of the infarct. Several connections among the bundles of surviving myocardium are seen at different levels, which may
serve as possible substrates for a reentrant ventricular tachycardia (VT). By definition, a reentrant VT continuously depolarizes some quantity of myocardial
tissue. As the mass of the myocardium in the protected channels inside the scar is small, it contributes only negligibly to the surface QRS complex. Therefore,
the QRS complex during VT initiates when the activation wavefront emanates from the border of the scar (from an exit). Panel C shows induction of VT
during ventricular-programmed stimulation (S1 and S2 represent pacing stimulus artifacts). Following S2, a long interval is seen on surface EKG followed
by initiation of VT. However, intracardiac recordings from inside the scar (LV) reveal presence of mid-diastolic potentials (thick arrows). Although essential
for initiation and maintenance of a reentrant VT, the electrical activation of these small bundles is not seen on surface EKG. Rather, they are only seen
during electrical recordings from inside the scar. In order to confirm that the area where the mid-diastolic potential is being recorded is part of the VT
circuit, entrainment maneuvers should be performed. The panel on the left summarizes entrainment findings that allow differentiation among possible regions
inside the scar area. In this panel: E = entrainment; EG-QRS = electrogram to QRS interval; PPI = post pacing interval; S-QRS = stimuli to interval;
VTCL = ventricular tachycardia cycle length. (Panel A and the panel on the left were obtained and modified from D’Avila et al. (371), while Panel B was
kindly provided by JMT de Bakker.)
branch block and right-axis deviation, and left upper septal
VT with narrow QRS.
Outflow VT is characterized by the manifestation of
repetitive monomorphic VT and exercise-induced sustained
monomorphic VT. The basic electrophysiologic mechanism
of outflow VT is widely accepted to be triggered automaticity
due to cyclic AMP-mediated calcium-dependent delayed af-
terdepolarization or catecholamine-dependent abnormal au-
tomaticity. The actual origin of outflow VT determined by
successful ablation distributes at various sites of the right and
left ventricular outflow tracts below the pulmonic and aortic
valves, above the pulmonic valve, or within aortic sinuses of
Valsalva. Compared with outflow VT, idiopathic VT arising
from the mitral and tricuspid valve annulus, the papillary
muscles, and the coronary sinus systems is rare in incidence.
The underlying electrophysiologic mechanism appears to be
the same as outflow VT.
ECG Features of VT/VF as Expression of the
Underlying Mechanisms and Site of Origin
The QRS morphology of VT on 12-lead ECGs is deter-
mined by the site of origin, that is, the site where the activation
of the normal myocardium arises in a case of a focal origin
or the exit site from a reentrant VT. The ability to localize the
region of origin on the basis of the ECG morphology directs
mapping to a specific area of the ventricles when VT ablation
is planned. ECG features are useful not only to identify the
region of interest but also to help differentiate an epicardial
or endocardial VT origin.
General Rules
Some general rules can be applied to the QRS analysis
during VT, regardless of the underlying substrate. First, QRS
width is affected by the proximity to the septum, narrower with
septal VTs; but also by the amount of myocardial disease,
being wider with poor overall ventricular conduction.
The appearance of a left bundle branch block (LBBB)-like
pattern suggests a right ventricular or left ventricular septal
origin, dominant R waves in V1 or dominant negative deflec-
tions in Lead I indicating a left ventricular exit. The frontal
plane axis indicates whether the exit is on the inferior wall
(superior axis) or on the anterior wall (inferior axis). The axis
direction, right versus left, may help to define further the re-
gion of origin. The mid precordial leads (V3 and V4) indicate
if the exit site is at the base or the apex; basal sites pro-
ducing dominant R waves and apical sites generating domi-
nant S waves. The presence of QR/QS complexes indicates
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TABLE 1
ECG Criteria for Localizing Site of Origin of Ventricular Tachycardia from Basal Left Ventricular Sites
S-P AMC Superior MA Superolateral MA Lateral MA
Lead I R or Rs Rs or rs rs or rS rS or QS rS or rs
Lead V1 QS or Qr qR R or Rs R or Rs R or Rs
Precordial transition∗ Early None None None None or late S wave
QRS ratio in leads II and III >1 ≤1 ≤1 ≤1 >1
∗Reversal of Q to R and vice versa ≤V3 (early) and ≥V5 (late S-wave appearance).
AMC = aorto-mitral continuity; MA = mitral annulus; S-P = septal-parahisian.
activation is moving away from the site where the complex is
registered. Finally, VTs that originate at the subepicardium
generally have slower QRS upstrokes in the precordial leads
than those with an endocardial exit.
Idiopathic VT
Idiopathic VTs usually arises from the right ventricular
outflow tract (RVOT) and less frequently from the left ven-
tricular outflow tract (LVOT), but can also originate around
the mitral or tricuspid annulus, from the papillary muscles,
or involve the fascicles of the LV. ECG features can help us
to distinguish the different regions of origin. RVOT VTs have
an LBBB-like morphology, inferior axis in the frontal plane,
and a precordial QRS transition that begins no earlier than
V3. Free wall sites can be differentiated from the septal ones
by a later QRS transition and wider QRS duration and notch-
ing.47,48 LVOT VTs may arise from the LVOT and/or the aortic
cusp region.49,50 The ECG has also an LBBB-like configu-
ration, inferior axis in the frontal plane and a precordial QRS
transition in lead V2 or V3 in VTs originating from the right
coronary cusp, and in lead V1 or V2 in VTs originating from
the left coronary cusp. It has also been described that a broad
R-wave duration in V1 or V2 is present in the cusp region
(R-wave duration index ≥50%) versus the RVOT.44 A small
proportion of idiopathic VTs can arise from sites around the
tricuspid annulus, more frequently at the septal portion. The
QRS morphology is usually positive in lead I and aVL as
well as V5 and V6.51 Idiopathic VTs can also infrequently
originate from the basal left ventricular endocardium. The
ECG analysis of the QRS morphology in I and V1, the ratio
of the QRS complexes in II/III, and the precordial transition
pattern, may be helpful in differentiating medial from lateral
locations around the mitral annulus (MA) (Table 1). Medial
sites (septal parahisian and aortomitral continuity) have nar-
rower QRS, initial negative forces in V1, and predominant
positive forces in I. The QRS ratio in II/III is >1 in septal
parahisian and lateral MA and <1 in aortomitral continuity,
superior MA, and superolateral MA.52 Annular VT as with
preexcited tachycardia will show dominant R waves in V5
and V6.53
Idiopathic fascicular left VTs have also characteristic ECG
features including a right bundle branch block (RBBB)-like
pattern left axis deviation (in a small proportion right infe-
rior axis deviation) with a short QRS duration (≤140 ms)
and a rapid QRS upstroke due to initial activation of the
Purkinje system. Recently, VT originating from the papil-
lary muscles (PAP) in patients with or without prior myocar-
dial infarction has been described. The ECG characteristics
for PAP have been differentiated with those of the fascicular
VTs.54,55 The PAP had broader QRS complex (150 ± 15 ms
vs 127 ± 11 ms). All of the fascicular arrhythmias (vs none
of the PAPs) had an rsR’ pattern in lead V1. All fascicular
arrhythmias had a left anterior or posterior hemiblock pattern
including discrete Q waves in leads I and aVL or I, II, III,
respectively. The PAP arrhythmias from the posterolateral
or anterolateral PAP showed the same axis as the fascicular
VTs of the corresponding fascicle but without the discrete Q
waves in limb leads.
ARVC
The typical LBBB VT morphologies are closely related
to the area that is predisposed to fibrofatty replacement of
myocardium, which is the “triangle of dysplasia.”56 Quite
typically for VT in ARVC compared with idiopathic VT,
the QRS complexes are fragmented and depolarizing forces
suppressed, which leads to lesser steepness of the QRS up-
stroke. In the literature, the most frequently described VT
morphologies are intermediate or inferior axis and LBBB or
superior left axis and LBBB. In the study from Niroomand
et al., 48% of the tachycardias displayed an inferior axis,
27% an intermediate, and 20% left/superior axis.57 In con-
trast, in only 10% of the cases with idiopathic VT the axis
was intermediate or superior. VT pleomorphism is another
frequent finding in patients with an ARVC, and the literature
provides numbers ranging from 1 to 12 different morpholo-
gies/patient.58
Postinfarction VT
The12-lead ECG can be used to identify the exit site
of postinfarction VT, although its localizing value has been
questioned and is subject to many limitations.59-61 The fol-
lowing criteria are helpful in assigning a specific endocar-
dial exit area within the heart to a particular VT morphol-
ogy:59,61-63 apical location often displays Q waves in leads
I, V1 through V6; basal location often displays R waves in
leads I, V1-V6; septal location LBBB morphology; poste-
rior location often Q waves in the inferior leads associated
with R waves in lead I and precordial leads. The presence of
RBBB versus LBBB morphology additionally influences the
location of the VT exit site, in that LBBB morphologies have
their exit from the septum, whereas RBBB morphologies can
originate from the septum or the free wall.
There are specific VT morphologies that can be assigned
to a particular endocardial exit site, depending on the loca-
tion of a prior infarction.61 In patients with prior inferior
wall infarction, LBBB morphology with superior axis and
increasing R-wave progression from V1-V6 suggests infer-
obasal septum origin; RBBB morphology with superior axis
and reversed R-wave progression from V1-V6 suggests in-
ferobasal free wall origin; and, RBBB morphology with in-
ferior axis suggests inferolateral free wall origin. In patients
with prior anterior wall infarction, LBBB morphology with
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superior axis and negative precordial concordance suggests
inferoapical septum origin; LBBB morphology with inferior
axis, as well as RBBB morphology with inferior axis and
abrupt loss of R waves, suggest anteroapical septum ori-
gin. The VT morphology with the least predictive pattern is
the RBBB morphology with a superior axis, especially in
patients with prior anterior wall myocardial infarction.
Epicardial Origin of VT
The discrimination between endocardial versus epicardial
VTs is of great interest because the VT-ablation approach
will be completely different, requiring pericardial access and
epicardial mapping and ablation in a case of an epicardial
VT. Berruezo et al. demonstrated that the epicardial origin
of the ventricular activation can be recognized on the ECG
by a slurring of the initial part of the QRS complex (pseu-
dodelta).64 The duration intervals and cutoff values obtained
for the “pseudodelta wave” and “intrinsicoid deflection in
V2” obtained a high sensitivity and specificity in identifying
an epicardial origin of the VTs. Daniels et al.46 quantified
the slowed initial precordial QRS activation of the epicardial
LVOT VT by a novel measurement, the maximum deflection
index (MDI). The MDI is the result to divide the time to max-
imum deflection in precordial leads by the QRS duration. A
delayed shortest precordial MDI ≥0.55 identified epicardial
VT remote from aortic sinus of Valsalva with a high sensi-
tivity and specificity. Later, Bazan et al.65 showed that the
presence of a Q wave in leads that reflect local ventricular
activation may be useful to distinguish epicardial left VT in
patients without ischemic heart disease.
Pre- and Intraablation Patient Management
Preprocedural Evaluation of the Patient Undergoing
Catheter Ablation for the Treatment of VT
Routine preprocedural assessment in patients referred for
catheter ablation of cardiac arrhythmias comprises a careful
physical examination, electrocardiogram analysis, and labo-
ratory evaluation. In patients scheduled to undergo catheter
ablation for the treatment of VT/VF, additional steps in the
evaluation process are necessary.
Identification of presence and extent of obstructive coronary
artery disease
In patients with reversible myocardial ischemia, surgical
or percutaneous revascularization may be pursued to improve
patient outcome. Myocardial ischemia rarely results in recur-
rent sustained monomorphic VT. Therefore, in patients with
known coronary artery disease, further testing is warranted
only if the severity of coronary artery disease has not been
previously established or prior episodes of VT caused hemo-
dynamic compromise. In patients with frequent or incessant
VT, catheter ablation may have to precede assessment for
coronary artery disease in order to gain prompt control of the
ventricular arrhythmia.
Identification of etiology and extent of myocardial disease
The etiology and extent of myocardial disease need to be
defined prior to catheter ablation. At minimum, a transtho-
racic echocardiogram and usually assessment for coronary
artery disease are recommended. In patients with nonis-
chemic cardiomyopathy, further evaluation may include car-
diac computed tomography (CT) or magnetic resonance
imaging (MRI), in addition to endomyocardial biopsy.
Suspected peripheral vascular disease
In patients with suspected peripheral vascular disease,
further evaluation may be reasonable. Anticipating a diffi-
cult arterial approach, the operator may select the transseptal
route for left ventricular access.
Identification of type and burden of VT
The type and burden of VT needs to be identified. Ideally,
a 12-lead electrocardiogram should be obtained. In patients
with ICD, stored device data such as electrogram morphology
and cycle length may be used to identify the clinical VT.
Imaging
Preprocedural imaging
Cardiac imaging, either echocardiography, cardiac CT, or
MRI, is warranted in all patients with ventricular arrhythmias
to assess for the presence and severity of cardiac disease. It fa-
cilitates identification of anatomic variations serving as sub-
strate for VT initiation or impediment to successful catheter
ablation. In particular, preprocedural MRI is useful for the
identification of myocardial scar, ARVC, sarcoidosis, non-
compaction of left ventricle, and left ventricular aneurysm.
In patients with impaired ventricular function undergoing
left ventricular mapping, the presence of a left ventricular
thrombus needs to be excluded by transthoracic echocardiog-
raphy66-68 or other imaging tools. In patients with a history of
atrial fibrillation, transesophageal echocardiography should
be utilized to exclude the presence of a left atrial thrombus.
Intraoperative imaging
Coronary angiography is used to delineate the course
of the coronary arteries in relation to site of ablation. In-
traoperative intracardiac echocardiography (ICE) provides
an alternative means if ablation is performed within the
LVOT or the aortic cusps. Furthermore, ICE allows proper
identification of the papillary muscles55,69 Integrating elec-
troanatomic mapping with ICE provides the operator with a
3-dimensional (3D) anatomical reconstruction of the ventric-
ular chambers,70 and may facilitate differentiation of normal
from scarred myocardium and denote the presence of epi-
cardial scar necessitating pericardial mapping and ablation.
Newer strategies have integrated cardiac CT, positron emis-
sion (PET) CT or MRI with electroanatomic mapping sys-
tems. However, evidence is lacking that ICE or preacquired
volumetric imaging integrated into electroanatomic mapping
systems improves efficacy or safety of catheter ablation pro-
cedures.71
Anticoagulation Strategy
The thromboembolic risk of catheter ablation of VT/VF
may differ in relation to individual patient factors and ab-
lation site. Patients with structural heart disease undergo-
ing ablation within the left ventricle are at particularly high
risk. Therefore, it is recommended that left ventricular ab-
lation procedures be performed using systemic anticoagula-
tion. Table 2 summarizes different heparin regimens, throm-
boembolic events, and hemorrhagic complications during
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TABLE 2
Postmyocardial Infarction Ventricular Tachycardia
Thromboembolic Local Hemorrhage/
Complications TamponadeNo. Patients
No. with Post- No. TE CVA/ Hemorrhage/
Authors Patients MI VT Procedures Prophylaxis TIA Other Pseudoaneurism Tamponade
Morady72 15 15 15 5,000 ini, 1,000/hour 0 0 0 0
Kim73 21 21 30 4,000 ini, 1,000/hour 0 0 0 0
Rothman74 35 35 44 NA 0 1 1 0
Stevenson23 52 52 69 5,000 ini, 1,000/hour 1 0 1 0
Callans75 66 66 95 5,000 ini, ACT 250—300 3 0 0 2
Ortiz76 34 34 42 5,000 ini, 1,000/hour 0 0 0 0
Calkins77 146 119 171 ACT >250 4 1 1 3
O’Callaghan78 55 55 55? ACT >300 0 1 1 0
Borger ∗79 151 89 89 ACT >2.5–3 × baseline 2 0 0 1
Della Bella80 124 124 139 5,000–10,000 ini, ACT 200–250 1 2 0 0
O’Donnell81 109 109 109? ACT >250 1 0 8 3
Segal et al.82 40 40 44 ACT >250 2 0 2 3
Stevenson77 231 231 252 Heparin dose not specified 0 0 11 1
Total 1,079 990 1,154 14 (1.3%) 5 (0.5%) 25 (2.3%) 13 (1.0)
∗Data from this series refer to the 89 patients with post-MI VT.
CVA = cerebrovascular accident; ini = initial; MI = myocardial infartion; TE = thromboembolism; TIA = transient ischemic attack; VT = ventricular
tachycardia; ACT = activated clotting time.
RF catheter ablation in 1,079 patients as published in 13
series including patients with a history of myocardial in-
farction.23,72-83 Heparin regimens were usually controlled by
measuring the activated clotting time (ACT), with a common
target value of ≥250 seconds. The most serious complica-
tions were cerebrovascular accidents (CVA) and transient
ischemic attacks (TIA) with an incidence of 1.3%. Pericar-
dial tamponade, likely due to pericardial hemorrhage, oc-
curred in 1% of cases. Local hemorrhagic complications
(large hematomas or arterial pseudoaneurysms) occurred in
more than 2% of patients.
Anticoagulation for right ventricular mapping and ablation
Unless other risk factors are present, catheter ablation
within the right ventricle does not require use of systemic
heparin. Some centers may use heparin for the prevention
of deep venous thrombosis and pulmonary embolism, es-
pecially if a prolonged procedure is anticipated. Similarly,
patients with a prior history of deep venous thrombosis or
pulmonary embolism, presence of a hypercoagulable state
(e.g., factor V Leiden), or right-to-left cardiac shunt should
undergo systemic anticoagulation. Anticoagulation is not
needed following the procedure.
Anticoagulation for left ventricular mapping and ablation
in the absence of structural heart disease
Systemic anticoagulation with intravenous heparin is rec-
ommended intraoperatively for all patients undergoing left
ventricular catheter ablation. In case of extensive ablation,
aspirin may be given postoperatively at a dose from 75 mg
to 325 mg for 4 to 8 weeks. Some centers advocate postpro-
cedural warfarin use in patients with additional risk factors
for thromboembolism.
Anticoagulation for left ventricular mapping and ablation
in the presence of structural heart disease
Preoperative screening for left ventricular thrombus is re-
quired in all patients. Mobile left ventricular thrombus is an
absolute contraindication to catheter ablation. In contrast, left
ventricular catheter ablation may be performed despite the
presence of laminated thrombus, if the patient has been ther-
apeutically anticoagulated with warfarin for at least 4 weeks
prior to ablation. Intraoperative anticoagulation schemes dif-
fer between centers. Unfractionated heparin is administered
to maintain a target ACT ≥250 seconds. Certain electrode
arrays with high thrombogenicity may require an ACT≥300
seconds. Pericardial access should be obtained prior to ven-
tricular instrumentation and the subsequent need for intrapro-
cedural anticoagulation.
Sedation and Analgesia
In order to provide safe sedation and analgesia during
catheter ablation for VT, a careful preprocedural assessment
of the patient is indicated. Consultation with an anesthesi-
ologist should be considered in high-risk patients. Trained
personnel familiar with monitoring of blood pressure, pulse,
and oxygen saturation need to be present throughout the pro-
cedure as dictated by state and institutional policy.84 Training
requirements for the safe administration of intravenous seda-
tion and analgesia should follow the recommendations of the
American Society of Anesthesiologists.85 Conscious seda-
tion or general anesthesia is commonly used during catheter
ablation of VT. The optimal strategy depends on the patient
characteristics. Conscious sedation is the preferred strategy
in patients with catecholamine-sensitive VT or if VT was
not inducible during a prior electrophysiology study. During
conscious sedation, different drugs may be added to acquire
deeper levels of sedation to prevent patient movement during
epicardial puncture. The level of sedation may subsequently
be titrated to allow induction of VT. General anesthesia is
favored in children and in patients with risk for airway ob-
struction. The advantages of general anesthesia include en-
hanced patient comfort and minimizing patient movement,
thereby facilitating vascular and epicardial access as well as
catheter manipulation and ablation. In addition, ventilator
cycle length settings may be adjusted to minimize catheter
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movement during ablation. Last, the use of paralytic agents
during epicardial mapping and ablation may preclude ac-
curate identification of the phrenic nerve using high output
pacing.
Mapping Methods for VT Ablation
The mapping techniques employed to guide VT ablation
depend on the likely mechanism of VT and the nature of its
substrate. Focal origin VTs can be localized by activation
mapping and/or pace mapping. VTs that are due to scar-
related reentry often arise from large reentry circuits. Acti-
vation mapping and pace mapping alone can be misleading.
Entrainment mapping can be useful, but is limited when VT
is unstable. Substrate mapping is useful in these cases. Map-
ping procedures commonly combine these different mapping
techniques to facilitate identification of desirable ablation
sites.
Activation Mapping
Activation mapping is the method of choice for identify-
ing a hemodynamically stable, focal VT . It may be performed
by point-by-point mapping with a roving mapping catheter,
with the use of multiple catheters or multielectrode arrays.
Electrograms may be recorded with unipolar, bipolar, and/or
combinations of both recording methods as each has dif-
ferent advantages and weaknesses. Unipolar recordings are
typically obtained with minimal filtering (e.g., high-pass fil-
ter corner frequency set to 0.5 Hz or lower), in which case
the morphology of the recordings provides potentially useful
information.86-88 A QS configuration is typically seen at the
origin of focal arrhythmias. An rS or RS configuration in-
dicates a wavefront moving toward the recording electrode,
hence the recording site is not at the origin of a focal VT.
These morphologic characteristics are not sufficient, how-
ever, to be the sole guide to a VT origin, as a qS complex
may be recorded over a region adjacent to the focus. Unipolar
recordings contain a substantial contribution from far-field
signals due to depolarization of myocardium remote from
the recording site. In areas of scar, the far-field signal can ob-
scure low-amplitude signals of interest that arise from slow
conduction regions. Therefore, bipolar recording is favored
for catheter mapping of scar-related VT. In bipolar record-
ings much of the far-field signal is subtracted out, facilitating
recognition of low-amplitude signals.86,88,89 Local activation
is usually taken as the first peak of the bipolar signal. In bipo-
lar recordings, spatial resolution is reduced by the fact that
a discrete potential of interest may be due to depolarization
of tissue beneath either or both of the recording electrodes.
When the signal of interest arises from tissue beneath the
proximal electrode ablation at the distal electrode may fail.
This situation can be potentially recognized by simultane-
ous recording of unipolar and bipolar electrograms and high
pass filtering the unipolar electrogram to reduce the far-field
contribution to the signal.
For most activation sequence mapping a clear point on
the QRS complex provides a useful fiducial point for mea-
surement. The relation of this point to the onset of the QRS
is determined. Depolarization that precedes the QRS onset,
typically by less than 30% of the VT cycle length, is re-
ferred to as presystolic. Electrograms that are depolarized
between the QRS complexes, in “electrical diastole” are of-
ten referred to as diastolic electrical activity. For focal VTs,
such as idiopathic outflow tract VT, activation at the focus
precedes the onset of the QRS and is the earliest point of
activation in the ventricle. Most scar-related VTs are due to
macroreentry. There is no earliest or latest point of activa-
tion. Presystolic activity is recorded from reentry circuit exit
regions. Depolarization of isthmuses (channels) proximal to
the exit is expected to occur during electrical diastole, often
indicated by isolated potentials. Definition of the entire reen-
try circuit by activation mapping traces a continuous path
of activation covering the entire tachycardia cycle length. In
scar-related macroreentry VT, there are several factors that
limit creation of complete activation maps. Identification of
true local activation time can be difficult in areas with frac-
tionated and split potentials, some of which can be far-field
activation. Portions of the reentry circuit can be intramural
or epicardial and not sampled. Diastolic activity occurs in
some bystander regions in scars that are not part of the reen-
try circuit. For macroreentrant VTs, a complete activation
map can be achieved for some stable VTs. In scar-related
VTs, activation mapping is not a reliable method. Activation
mapping data are often combined with entrainment mapping
to distinguish bystander sites from reentry circuit sites and
with substrate mapping data.
Activation mapping is the basic mapping technique in tar-
geting idiopathic VT or PVCs originating from the RVOT
or PAP, albeit pace mapping can provide additional assis-
tance.55,90 It is also the primary mapping tool in the abla-
tion of His-Purkinje-related VTs, which includes verapamil-
sensitive fascicular left VT.91-93 It is also the primary method
for targeting foci that are triggering recurrent episodes of
VF or polymorphic VT with or without structural heart dis-
eases.42,94-96 Successful target sites often have a sharp po-
tential, consistent with a Purkinje potential, preceding the
QRS onset of VT or PVCs by 20 to 160 ms. In some pa-
tients PVCs that arise from the infarct scar originate from the
exit site of a reentrant VT, such that activation mapping of
the PVCs can be used to target ablation of a macroreentrant
VT.97
The spatial and temporal resolution of point-by-point acti-
vation mapping is limited by the number of contact electrodes
and the time required. Systems that provide greater spatial
sampling are available. Basket catheters that have splines
with multiple electrodes can be deployed in the ventricle.98
These catheters have been used successfully to guide ablation
of idiopathic RVOT VT/PVCs, and are of particular interest
in patients with infrequent arrhythmia that limits mapping.98
Spatial sampling is limited by the interspline and interelec-
trode distances, and endocardial contact is often limited due
to the complex geometry of the ventricles. These catheters
are not commonly used. The noncontact multielectrode ar-
ray mapping system records signals from a 64-electrode ar-
ray and calculates 3,000 virtual unipolar electrograms over
the endocardial surface that is defined by roving mapping
catheter99 The sequence of depolarization is displayed visu-
ally from single beats, making it potentially useful to define
activation sequence during nonsustained and poorly toler-
ated arrhythmias. It is not accurate for points that are more
than 4 cm from the multielectrode array, and must be used
with caution in dilated ventricles.100,101 Filter settings have a
significant effect on the activation maps and unipolar virtual
electrograms with a QS onset, consistent with a VT origin,
must be confirmed by inspection to ensure that they are not
due to artifact. Studies using the system to define areas of
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scar for substrate mapping and intramural foci support feasi-
bility.101-103
Pace Mapping
Pace mapping is pacing in the absence of tachycardia to
assess the possible relation of the pacing site to a tachycardia
focus or reentry circuit.104,105 Unipolar pacing from the dis-
tal ablation electrode may be performed, but causes a large
stimulus artifact in the surface ECG.106 Bipolar pacing from
the closely spaced distal electrodes of the mapping catheter
is more commonly used. Although the possibility for cap-
ture at either the distal or proximal bipolar electrodes can
reduce spatial accuracy, this does not appear to be a ma-
jor limitation107,108 Use of current strengths near threshold
should improve accuracy by limiting the size of the virtual
electrode in the tissue and preventing capture of myocardium
distant from the pacing site. Pacing thresholds ≥5 to 10 mA
typically indicate insufficient electrode-tissue contact or in-
excitable scar areas. The morphology comparison should be
based on the 12-lead ECG. At the VT origin or exit, the paced
QRS resembles the VT QRS. For idiopathic VTs, an exact
match with all amplitudes and notches in 12-lead ECGs is
sought. Studies comparing detailed analysis of QRS mor-
phologies during pace mapping for outflow tract VT have
shown that the resemblance to VT progressively decreases at
sites further from the VT focus, but good pace-map matches
can be seen over areas of more than 1 cm and more than 2
cm from the successful ablation site in some patients.105,109
Catheter ablation at sites with a “perfect” pace map are typ-
ically successful.109,110 Pace mapping can also be useful for
LVOT VT, but is less reliable for arrhythmias originating
from the aortic sinus cusps.111
Thus, pace mapping is likely to be less accurate than acti-
vation mapping. In contrast to activation mapping, however,
pace mapping can be utilized during sinus rhythm, in the
absence of VT. Therefore, it is particularly useful for identi-
fying an initial region of interest when VT is rapid or difficult
to induce. The quality of the information obtained from pace
mapping is critically dependent on the spatial resolution of
the mapping procedure within the 3D chamber/area of in-
terest. Therefore, the combination of pace mapping with 3D
mapping systems may be helpful to achieve better spatial
resolution than fluoroscopy alone.
Specific clinical applications of pace mapping are focal
VT and scar-related VT.
Scar-related VT
Pace mapping may also be used to define likely exit re-
gions and reentry circuit isthmuses for scar-related VT.112-115
The QRS morphology of the VT in the 12-lead ECG is an in-
dication of the location of the reentrant circuit exit site. Pace
mapping at the presumed exit site region from the “central
common pathway” or “isthmus” replicates the QRS mor-
phology of the VT with a relatively short (<40 ms) stimulus-
QRS interval. However, an exact exit site pace-map match
typically can be achieved over a relatively large area. It is im-
portant to recognize that pace mapping at reentry circuit sites
that are not near the exit may produce a QRS that is different
from the VT, even though ablation may be effective at that
site.115 Pace mapping also can provide additional information
relevant to the arrhythmia substrate. A long stimulus-QRS,
exceeding 40 ms, indicates slow conduction away from the
pacing site, which can be the substrate for reentrant VT.115
Areas of electrically unexcitable scar have been defined as
regions with a pacing threshold >10 mA.106 These areas may
indicate dense fibrosis that may form the border of a reentry
circuit path.
Entrainment Mapping
In patients with scar-related VT, the anatomic complexi-
ties of reentry circuits and regions of slow conduction make
it difficult to define adequately reentry paths with activation
mapping alone. A schematic drawing of a hypothetical reen-
try circuit with an isthmus, loops, and bystander is shown in
Figure 2. The reentry wavefront travels from the entrance of
the isthmus to the center and then exit of the isthmus. It then
propagates around the scar as an outer loop, or through the
scar as an inner loop, to reach the entrance. Entrainment find-
ings consistent with different sites in and remote from reentry
circuits are summarized in Figure 2. Four observations during
entrainment are analyzed to identify the relation of the pac-
ing site to the reentry circuit. The postpacing interval (PPI),
measured from the last stimulus that entrains or resets tachy-
cardia to the next depolarization at the pacing site, represents
the conduction time from the pacing site to the reentry circuit,
through the circuit, then back to the pacing site. Thus, the
PPI-tachycardia cycle length (TCL) difference indicates the
conduction time between the pacing site and the circuit. The
PPI-TCL difference is not influenced by QRS fusion during
entrainment and can help identify loops in the reentry circuit
as well as isthmuses where pacing entrains tachycardia with
concealed fusion.116 The PPI-TCL difference is based on the
assumption that the recorded ECG represents depolarization
of the pacing site. Inability to distinguish far-field potentials,
which are due to depolarization of tissue, remote from the
pacing site, from the local electrogram is a source of error.117
Recordings from the pacing site are not always obtainable
or interpretable due to electrical noise after the stimulus.
However, because the beat following the last entrained QRS
(QRSn+1) is not influenced by QRS fusion during entrain-
ment, the QRSn+1 can be used as a timing reference to assess
the PPI-TCL difference.118 The stimulus-QRSn+1 to local
electrogram difference indicates the PPI-TCL difference al-
lowing assessment when the PPI cannot be measured directly
from the pacing site electrograms. When pacing is performed
from the protected isthmus, the QRS is the same as the VT
QRS and there is no evidence of QRS fusion (concealed
entrainment). Clear fusion will be observed when pacing
is performed from an outer loop region. If the pacing rate
is substantially faster than the VT, fusion will also be seen
when pacing at the entrance of the protected isthmus. At sites
with concealed entrainment bystanders can be identified by
comparing the stimulus to QRS and electrogram to QRS in-
tervals. Bystander areas have a stimulus-QRS interval longer
than ECG-QRS interval. In this situation, the interpretation
of the PPI-TCL difference is not necessary. The stimulus-
QRS indicates the conduction time from the pacing site to
the reentry circuit exit. Longer stimulus-QRS intervals indi-
cate likely inner loop sites. At outer loop sites entrainment
occurs with QRS fusion but the PPI indicates that the site
is in the reentry circuit. Successful interruption of VT by
ablation is low.119 Sites where ablation is most likely to in-
terrupt reentry are those with features of an isthmus site with
a stimulus-QRS less than 70% of the VT cycle length and
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Figure 3. Electroanatomic mapping for
substrate ablation. A 3-dimensional left
ventricular endocardial voltage map is
shown in a patient with healed inferior
myocardial infarction and VT. A voltage
map constructed during sinus rhythm is
designated by the color display: sites with
bipolar voltage <0.5 mV are coded in red,
sites with voltages >1.5 mV in purple, and
the border zone of intervening voltages
with the intervening colors. In this exam-
ple, the location of late (black dots) and
fractionated (pink dots) electrograms are
also displayed.
an isolated potential.119-121 Pacing for entrainment mapping
occasionally produces VT termination without global cap-
ture.122 This finding is likely to indicate that the pacing site
is in a reentry circuit isthmus that is a desirable target for
ablation. Capture of the stimulus may occur with block of
the orthodromic wavefront between the stimulus site and the
exit and collision of the stimulation wavefront traveling in
the antidromic direction in the circuit. Similarly, mechanical
termination of VT can also be an indication that the catheter
is at a reentry circuit site.123
There are many limitations of entrainment mapping. A sta-
ble tachycardia is required. Pacing that terminates or alters
tachycardia complicates mapping and renders the entrain-
ment mapping findings uninterpretable. It is difficult to apply
for unstable VTs, although limited substrate mapping com-
bined with limited entrainment mapping at selected sites fol-
lowed by prompt tachycardia termination can be used to help
locate a region for ablation during sinus or paced rhythm.33
Substrate Mapping
In a recent multicenter ablation study, 31% of patients
had only unmappable VT and 38% had both mappable and
unmappable VT morphologies targeted.83 Substrate mapping
is the approach of utilizing techniques that allow the majority
of the mapping and ablation to be performed in sinus rhythm,
and is required in many patients with VT in the setting of
structural heart disease. It is often combined with limited
activation and entrainment mapping. The concept of substrate
mapping evolved from the success of surgical subendocardial
resection for post-MI VT, which established the physical
link between the VT circuit and the infarct scar.124 Infarct
regions are identified from areas where electrograms have an
amplitude of <1.5 mV (bipolar electrograms recorded from
catheters with a 4-mm tip electrode, 1 mm interelectrode
spacing and filtered at 10–400 Hz)113,125 (Fig. 3). This voltage
threshold has also been applied to identify areas of scar in
nonischemic cardiomyopathies, and ARVD.126,127
In patients with scar-related VT, the low voltage area is
often large, such that complete ablation of the area or com-
plete encircling ablation is often not feasible, nor necessarily
desirable. There are several concepts that guide selection of
ablation targets, all determined by different philosophies re-
garding the relationship of the VT circuit to the substrate.
The first concept was pace mapping to identify exit regions
in the border zone of the scar.113 Linear ablation lesions
were placed through each exit region, extending away from
the border region into the denser scar due to the recogni-
tion that the critical isthmus may be deeper within the scar.
A line of lesions may be placed parallel to the scar border
within the low voltage area encompassing the exit region.128
These strategies, although successful, are limited by their fo-
cus on individual VTs, requiring induction of VT to assess
QRS morphologies for guidance during pace mapping, mak-
ing it difficult to conceive of substrate ablation of undetected
morphologies. Several investigators have targeted all isolated
late potentials present during sinus rhythm or ventricular pac-
ing, which are often present at reentry circuit isthmus sites
identified for mappable VTs.129 In some patients, areas of
unexcitable scar that may be border forming for reentry cir-
cuits have been defined to attempt to identify isthmuses for
ablation.106 Alternatively, a “channel” may be identified as
a region of relatively larger voltage bordered by low volt-
age within the scar.130,131 These different substrate ablation
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Figure 4. A Tuohy needle (right superior corner) and anatomy relevant to epicardial access is shown. The sagittal anatomic image indicates the path of the
needle for pericardial access (green line). Fluoroscopic images show contrast, a guide wire, and catheter in the pericardial space.
strategies have not been directly compared and differences
in outcomes are not apparent in the literature. Variations in
anatomy may also influence the effectiveness of the differ-
ent methods. Although ablation guided by substrate mapping
avoids the hemodynamic consequences of prolonged map-
ping during VT, the lack of a precise reentry circuit target
is compensated by extensive ablation lesion sets, which in-
creases the potential for complications. In a recent multi-
center study, major complications including worsening heart
failure were observed in 7.3% of patients, and 3.0% died
within 7 days of ablation.83
In general, substrate-guided ablation achieves a marked
reduction in VT episodes (usually measured by a re-
duction of ICD shocks) in patients with scar-related
VT.33,83,113,114,129,130 It is a reasonable approach for patients
with unmappable VT and may be combined with other map-
ping approaches in patients with mappable VTs.
Transthoracic Epicardial Mapping and Ablation
Recently introduced in 1995, transthoracic epicardial
mapping and ablation has recently become an important ad-
junctive or even a preferable strategy to eliminate a diverse
range of cardiac arrhythmias.132-136 Briefly, a regular Tuohy-
17G needle designed for epidural anesthesia is introduced
at the subxiphoid region at a 45◦ angle and gently advanced
under fluoroscopy until close to the cardiac silhouette. The
precise site of the needle tip is determined by injection of
1 mL of contrast media. When the needle enters the peri-
cardial space, contrast medium can be seen surrounding the
cardiac silhouette (Fig. 4). A wire and introducer sheath is
inserted, allowing a mapping catheter to be inserted into the
pericardial space, where it can be manipulated to explore the
entire surface of the right and left ventricles. Electrogram
recording and interpretation for epicardial mapping are es-
sentially the same as for endocardial mapping, including the
use of activation mapping, pace mapping, and entrainment
mapping. Epicardial mapping is facilitated by the smooth
epicardial surface, without the limitation of papillary mus-
cles, trabeculae, and chordae, as well as absence of catheter-
induced ventricular extrasystoles that are encountered during
endocardial mapping.
Standard RF ablation can be used during epicardial
catheter ablation, but the lack of circulating blood for convec-
tive cooling of the ablation electrode limits power delivery in
the pericardial space, potentially limiting lesion creation and
efficacy of standard RF ablation.137 Irrigated RF ablation
allows greater power delivery and increased lesion size that
can be effective even when the epicardial target is covered by
fat.137,138 External irrigation requires intermittent drainage of
the pericardial space to prevent tamponade. Alternatively, use
of an introducer that is larger than the mapping catheter al-
lows aspiration around the ablation catheter. The amount of
fluid infused can also be limited.
Risks of epicardial mapping and ablation
The potential for coronary artery injury is a major con-
cern. There are 3 potential means by which damage could
occur to the coronary arteries during transthoracic epicar-
dial mapping and/or ablation. The needle can perforate a
coronary artery during access; the ablation catheter or sheath
could lacerate an epicardial vessel, which is unlikely because
the coronary vessels are covered by the visceral pericardium,
and the major concern is the risk of RF ablation on a coro-
nary artery. Experimental data suggest that coronary artery
occlusion depends on the vessel caliber.137,139 It is recom-
mended that proximity to the coronary arteries be defined
by a coronary angiogram if the ablation site is suspected of
being within 12 mm of a coronary vessel. On the other hand,
there are centers that do not perform routine angiograms
without any occurrence of acute and chronic coronary
events.46,140
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Imaging Tools, Energy Sources, and Catheters
for VT/VF Ablation
Imaging Tools
Although imaging techniques at the present time play
only a minor role in the field of catheter ablation of VT,
as compared with A Fib, they do serve an important func-
tion both in preprocedural planning and in postprocedural
follow-up. In addition, identification of the underlying heart
disease and visualization of a potential arrhythmogenic sub-
strate may facilitate selection of appropriate mapping and
ablation strategies during catheter ablation of VT141 and will
likely increase the role of pre- and periprocedural imaging
techniques.
Echocardiography
Transthoracic echocardiography serves as a reliable tool
to rule out ventricular thrombi before left ventricular proce-
dures. Additionally, it helps to identify relatively infrequent
cardiomyopathies associated with VT, for example, ARVC
and HCM, and is used for postprocedural detection of peri-
cardial effusions and cardiac tamponade, respectively. Trans-
esophageal echocardiography may be used in patients with
atrial fibrillation or flutter to detect thrombi within the left
atrium and the left atrial appendage, respectively, to prevent
thromboembolic events when a transseptal access to the left
ventricle or cardioversion are required. Severe atheroma in
the aorta detected on transesophageal echo may encourage
the operator to avoid the retrograde approach to the left ventri-
cle. ICE applied from the right atrium and the right ventricle
has been used for real-time imaging during VT ablation pro-
cedures.142 It allows for visualization of scarred tissue and
thus may help to identify the target area of ablation. ICE may
guide ablation of RVOT and LVOT VT by visualizing the
relationship between semilunar valves and coronary artery
ostia, respectively, and the sites of VT origin.143 In a small
cohort of patients with VT originating from PAP, ICE helped
to establish the site of origin and to guide successfully RF
ablation.55
Cardiac CT and MRI
Both cardiac CT and MRI are valuable tools for assess-
ing cardiac anatomy and function and for identifying struc-
tural abnormalities serving as arrhythmia substrate. Delayed
contrast-enhanced MRI delineates regions of scar tissue po-
tentially forming part of the arrhythmia substrate in patients
with ischemic and nonischemic cardiomyopathies.144,145 Ad-
ditionally, this imaging technique allows for determining a
specific etiology of nonischemic cardiomyopathies predis-
posing for a higher susceptibility for VT, such as myocardi-
tis, sarcoid, and ARVC. Feasibility of catheter navigation
and ablation in the left ventricle guided by registration of
preacquired MRI with real-time electroanatomic mapping
was demonstrated in a porcine infarct model.146 Ablation
catheters were successfully positioned to intracardiac target
sites under direct visualization by MRI fluoroscopy. Visu-
alization of ventricular anatomy and obstacles of procedural
success, for example, epicardial fat in case of epicardial map-
ping approaches, and the possibility of navigation and abla-
tion in the ventricular chambers has the potential to reduce
procedure time, decrease the rate of complications, and in-
crease success rate.74,147 One potential disadvantage remains
the concerns of the safety of MRI in patients with implanted
devices. Increasing data suggest that MRI at 1.5 T is possi-
ble when appropriate precautions are taken,148 and reports of
MRI at 3 T have been published for patients with implantable
defibrillators.149 Industry is also working to improve the MRI
compatibility of devices.
Other imaging tools
Cardiac catherization provides valuable information about
the coronary arteries, LV function, and ventricular thrombi,
representing a relative contraindication to catheter ma-
nipulation. Angiographic evidence of akinetic or dyski-
netic bulgings within the right ventricle is highly spe-
cific to ARVC.150 In patients with scar-related VT, PET
CT may be beneficial, as it provides additional tissue
characterization by displaying metabolic and morphologic
information.147,151,152
Energy Sources and Catheter Technologies
for VT Ablation
The principal problem facing catheter technology when
applied to VT ablation is to deliver a controlled lesion to
abolish the arrhythmia substrate but not so big as to damage
nonarrhythmogenic tissue. Induction of very limited tissue
damage may be desired during catheter ablation of focal
idiopathic VT. However, many patients with VT have a large
arrhythmia substrate involving endocardial, intramural, as
well as epicardial structures. In these patients, more extensive
tissue lesions may be required. Thus, from a biophysical
perspective catheter ablation of VT is a true challenge.
Energy Sources
RF ablation
Since its first description in 1978, RF energy has become
the most commonly, if not exclusively used energy source
for catheter ablation of all VT entities.153-157 RF alternating
current is usually administered with a continuous sinusoidal
unmodulated waveform of 300–1,000 kHz and allows the
generation of well-circumscribed myocardial lesions. The
most important mechanism of myocardial necrosis induc-
tion is based on the conversion of electrical energy into heat
within the myocardial tissue.158 (Fig. 5) The extent of the
tissue damage depends on the duration of RF energy applica-
tion158-160 and the temperature in the resistive heating zone
with higher RF power delivery invigorating an increase in
lesion size.161 However, at a certain energy level electrode
overheating may occur leading to coagulum formation and
charring on the tip electrode accompanied by a rapid in-
crease in electrical impedance that in turn leads to a loss
in effective myocardial heating.162 To prevent overheating at
the electrode-tissue interface, temperature-controlled energy
application systems have been developed. A thermistor or
thermocouple embedded in the tip of the ablation catheter
allows temperature monitoring at the electrode-tissue inter-
face during energy application. Maximal RF energy (usually
50 W) is delivered until the preselected target temperature
has been reached and thereafter automatically titrated down
to maintain the target temperature. The extent of lesion for-
mation not only depends on RF duration and power but also
on nonmeasurable variables like electrode-tissue contact and
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Figure 5. Comparison of radiofrequency
(RF) energy for lesion formation and risk
of steam pop and thrombus. Left panel: RF
ablation using a nonirrigated electrode
results in thrombus formation when the in-
terface temperature between the electrode
and the tissue or the electrode and blood
reaches 75–80◦C. Center panel: RF ab-
lation using a saline-irrigated electrode
prevents thrombus. However, a higher RF
power application produces a focal hot
spot 2–3 mm below the surface, resulting
in steam formation within the tissue and
a steam pop. Right panel: Ultrasound en-
ergy at 9 MHz penetrates myocardial tis-
sue to a depth of 5–6 mm and produces
a homogeneous active tissue heating, re-
sulting in a deeper lesion with a lower risk
of steam pop and thrombus.
orientation (perpendicular vs parallel to the tissue) and ex-
ternal cooling by the circulating blood flow.
Irrigated RF ablation
Despite a lack of randomized trials comparing different
approaches for VT ablation, there is general agreement that
irrigated electrodes provide advantages over standard RF ab-
lation in the setting of scar-related VT. Active cooling of the
ablation electrode, either by circulating fluid within the elec-
trode (closed loop) or by flushing saline through pores in the
electrode (open irrigation),176 allows greater energy delivery
before a critical temperature rise at the electrode-tissue inter-
face occurs, and larger lesion formation.158,163-166 Although
currently no clinical studies are available directly comparing
closed loop irrigation with external irrigation, it seems that
the latter technique may have distinct advantages. External
saline irrigation resulted in a lower interface temperature and
decreased the risk of thrombus formation and severe tissue
damage as compared with closed loop irrigation at similar
levels of impedance, lesion depth, and tissue temperature in
an experimental preparation.167 However, administration of
relatively large amounts of saline using external irrigation,
which may exceed 2,000 mL, may cause hemodynamic or
respiratory compromise especially in patients with severely
impaired left ventricular function, which necessitates con-
tinuous monitoring of fluid balance. Saline irrigation cools
the electrode itself and thus impedes electrode temperature
feedback resulting in an increased risk of unnoticeable tissue
overheating. If the intramyocardial temperature exceeds ap-
proximately 100◦C, gas bubble formation may occur leading
to an explosion of steam that may in turn cause myocar-
dial perforation and cardiac tamponade. These “steam pops”
are audible in the electrophysiological laboratory but usu-
ally without consequences when energy is applied to the left
ventricle. However, perforation of the right ventricle after
“popping” has been reported.
Three large studies showed the feasibility of both internal
and external irrigation in ablation of VTs in the presence of
structural heart disease.77,83,168
Pulsed RF ablation versus continuous RF ablation
In addition to the abovementioned techniques, energy de-
livery to the myocardium can be influenced by the mode of
RF application. RF energy can be applied either continu-
ously over a certain period of time or repetitively with the
single periods (duty cycle) lasting a few milliseconds. The
latter approach, referred to as “pulsed RF ablation,” allows
the application of higher energy levels to the myocardium
at comparable electrode temperatures169 As compared with
continuous RF current delivery, the pulsed mode is associated
with higher intramyocardial temperatures and larger lesion
depths in vitro and in vivo.169,170
Alcohol ablation
Chemical ablation for VT is based on cytotoxic and irre-
versible tissue-damaging effects of ethanol and other agents
leading to myocardial necrosis and coronary vessel occlu-
sion with resultant ischemic injury. Before ethanol applica-
tion is performed, it is crucial to identify the target coronary
artery that supplies blood to the arrhythmogenic area. One
means of target vessel identification is by selective injection
of cooled saline, radiographic contrast medium, or antiar-
rhythmic drugs into different coronary branches.171-173 VT
termination identifies the branch supplying the arrhythmo-
genic substrate. Alternatively, mapping of diastolic potentials
as well as entrainment and pace mapping may be performed
from inside the coronary artery to locate the critical reen-
try circuit isthmus as for standard VT approaches.174 After
an appropriate target branch has been identified, ethanol is
applied in a manner similar to the approach used for septal
alcohol ablation in patients with obstructive HCM. Ethanol
ablation has moderate success rate and bears potential of se-
rious complications including permanent complete atrioven-
tricular block, pericarditis,171,173 reflux of ethanol into adja-
cent vessels leading to infarction of unintended myocardium,
and a worsening of heart failure due to a significant loss of
myocardium. Consequently, ethanol ablation should be con-
sidered only in selected patients suffering from highly symp-
tomatic drug-refractory VT who failed previous endocardial
and/or epicardial RF ablation.
Cryoablation
For more than 2 decades, cryoenergy has been success-
fully used for ablation of ventricular myocardium during sur-
gical ablations of VT.172,175,176 Cryoablation produces more
circumscribed and generally smaller lesions as compared
with RF current. It possibly involves less damage to adja-
cent coronary arteries in the setting of epicardial ablation as
compared with RF ablation.177,178 Currently, no data from
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controlled clinical studies exist concerning the use of cry-
oenergy for catheter ablation of VT.
Other energy sources
Other energy sources that have been investigated for
catheter ablation of ventricular tachycardias include high-
intensity-focused ultrasound, laser energy as well as radi-
ation energy applied transcutaneously. No clinical studies
exploring these energy sources have been performed so far.
Ablation Catheters and Electrode Design
Electrode catheters used for ablation of VT usually have a
size of 7.5 French and unidirectional or bidirectional steering
capabilities. RF energy is usually delivered via the distal tip
of the electrode catheter. Currently, platinum-iridium is the
most commonly used catheter tip material. One advantage of
RF ablation is the simple design of the energy delivery sys-
tem, that is, a wire connects a generator to the tip electrode.
In principle, larger electrodes allow the application of higher
energy levels to the tissue due to greater exposure to the
circulating blood resulting in more effective electrode cool-
ing.179 For conventional nonirrigated ablation procedures,
the length of the ablation electrode measures 4, 5, 8, and
10 mm. Ablation electrodes used for external irrigation ab-
lation have a 3.5 mm tip. The tip has 6 to 9 irrigation holes
that are used to homogeneously distribute the saline over the
ablation electrode during energy application.
Mode of Energy Application, Selection of Ablation
Catheters, and Energy Settings
The selection of the mode of RF energy application, that is,
nonirrigated versus irrigated ablation, the ablation catheter,
and the energy application setting depends on the type of VT
targeted by ablation.
Idiopathic outflow tract VT
These arrhythmias are focal in nature and the target tissue
consists of structurally nondiseased myocardium. Thus, ex-
tensive tissue injury is usually not necessary for successful
ablation. Steerable catheters with 4- or 5-mm tip electrodes
and conventional nonirrigated energy application are gener-
ally used. The target temperature and output power should
be limited to a maximum of 60◦C and 30–40 W, respectively.
Duration of energy application should not exceed 30–60 sec-
onds. Because of the close anatomical relationship between
energy application sites and the ostia of the coronary arteries,
special caution is necessary for ablation of outflow tract VT
arising from the coronary cusps. Lower energy and temper-
ature levels may be adequate in this situation. Some investi-
gators recommend the use of lower target temperatures and
irrigated electrodes for left-sided idiopathic focal VT assum-
ing a higher risk of coagulum formation and thromboembolic
complications compared with ablation in the right ventricle.
Idiopathic fascicular VT and bundle branch reentrant VT
Due to the discrete nature of the arrhythmia substrate, the
same settings as for idiopathic outflow tract VT are recom-
mended.
VT originating from structurally diseased myocardium,
scar-related VTs
Catheter ablation of scar-related VT usually requires in-
duction of more extensive tissue injury to abolish the ar-
rhythmia substrate. Therefore, larger or irrigated electrodes
are preferred. Currently, there are no randomized studies
available comparing the efficacy and complications of this
approach with standard approach. Using 8 mm electrodes, a
maximum output power of up to 70 W with a target tempera-
ture of 70◦C or an impedance fall of 10 Ohms is reasonable in
the left ventricular myocardium. When irrigated ablation is
used output power is usually limited to 50 W, delivered dur-
ing a saline irrigation rate of 20–30 mL per minute, whereas
maximum catheter tip temperature should not exceed 50◦C.
Application duration of up to 90–120 seconds may be
chosen.
Epicardial ablation
Ablation of epicardial idiopathic focal VT may be per-
formed with standard 4-mm electrode catheters at power
settings between 25 and 40 W. Although the coronary arter-
ies are usually protected from severe injury induced by RF
energy by the high flow rate in the vessel (leading to signifi-
cant convection of heat), caution is recommended. Coronary
angiography may be performed before energy delivery and
energy setting may be adjusted to the individual situation. For
patients with structural heart disease undergoing epicardial
ablation, use of irrigated catheters may have significant ad-
vantages compared with conventional ablation; usually larger
lesion are desired that can be more reliably induced with
irrigated ablation. In addition, energy delivery during con-
ventional RF application may be limited by the fact that
application of relatively low power results in rapid heating
of the ablation electrode thereby preventing the generation
of large lesion due to the absence of cooling of the electrode
by the circulating blood. External irrigation leads to saline
accumulation in the pericardium during epicardial mapping
and ablation. Thus, periodic aspiration is necessary to prevent
hemodynamic compromise.
Ablation of VT/VF in Patients with Structural Heart
Disease: Techniques and Results
It is estimated that only 10–30% of patients with struc-
tural heart disease have VT suitable for ablation guided only
by activation and entrainment mapping during the arrhyth-
mia.113,180-182 In all the other patients, substrate-based map-
ping and ablation is required.
VT Ablation in the Setting of Ischemic Heart Disease and
Prior Myocardial Infarction
It has been demonstrated that the underlying mechanism
for VT in this setting is scar-related reentry.183-186 Although
an epicardial approach to catheter ablation may be needed in
some refractory patients, most of these VTs are amenable to
endocardial ablation.
Approach to catheter ablation of VT
It is important to obtain ECG recordings of all clinical
VT when available. Similarly, electrogram analysis from the
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device interrogation can be helpful in determining the cycle
length of the VT.
With the electrophysiologic procedure and ablation at-
tempts, an effort should be made to induce all potential mor-
phologically distinct VTs. Bundle branch VT, although less
commonly identified in prior myocardial infarction, should
be excluded. In patients without inducible sustained VT and
those with unstable VT, a substrate-based ablation is used.
Preferential channels of conduction in the scar can also be
identified by titrating the color range of the bipolar voltage
map from the typical setting of 1.5 to 0.5 mV to values down
to 0.2 mV to 0.1 mV. Pace mapping can be performed along
the dense scar border (0.5 mV) based on an assessment of
the 12-lead ECG morphology of all spontaneous and induced
VT. During pace mapping not only the similarity of the QRS
morphology to the pace map but also the time to the QRS is
assessed with intervals greater than 40 ms suggesting areas
of slow conduction that may approximate VT isthmus sites.
Sites of inexcitability defined by failure to capture at 10 mA
and 2 ms pulse width are also identified. These sites may also
serve as anatomic boundaries for VT circuits and help fur-
ther define channels of preferential conduction. Once bipolar
scar voltage mapping has been performed and pace map-
ping identifies areas of interest, ablation lines are created.
Lines are drawn to cross through sites of good pace maps
and defined channels. Lines have been effectively deployed
extending parallel to the scar edge in the border zone of the
scar. When lines are deployed parallel to the scar they should
be within the zone defined by a color range of 0.5 to 1.0 mV to
avoid damaging normal myocardium under subendocardial
scar. Lines perpendicular to the scar border and connecting
the scar to anatomic boundaries have also been successful
in eliminating VT. Many operators will draw lines in both
directions. In one study, critical isthmus was identified in
25 (63%) of the 40 patients and linear lesions, averaging
4.3 cm, abolished all inducible VTs.33,187 When targeting
late potentials, lesions are frequently applied in clusters to
eliminate the potentials. The endpoint for VT ablation tends
to be hierarchal in nature and is currently based primarily
on VT inducibility. The highest priority goes to trying to
eliminate VT that has been documented to occur clinically,
easily inducible VT with a slow rate and then finally all in-
ducible VTs. Because noninducibility is currently used as
the gold standard for the ablation procedure, it is recom-
mended that a standardized protocol of single, double, and
triple extrastimuli be used from at least 2 sites to define
success. Poorly tolerated VTs and the ongoing use of antiar-
rhythmic agents warrant a more aggressive substrate-based
ablation approach, if reproducible VT triggers have not been
identified.
Outcome of VT ablation
Successful acute termination of the targeted VT, when it
is stable and can be localized using activation and entrain-
ment mapping, can be achieved in 70% to 95% of patients
with limited RF application.121 However, following ablation,
VT can recur in up to 35% of patients.78,120,187 Outcome ap-
pears to be improved with irrigated ablation techniques.158
Substrate-based ablation results have produced comparable
outcome results in single-center reports. Recurrence rates
during intermediate-term follow-up has varied from 17%
to 36%, but patients with recurrences have demonstrated a
reduced frequency of VT episodes.33,113,125,129,130,189,190,191
Several multicenter prospective trials have assessed the ef-
ficacy of VT ablation in the post-MI patient.77,83,168,182 In
the first reported multicenter trial of 146 patients with map-
pable VT and ablation performed with an internally irrigated
catheter, 82% of the patients had coronary artery disease.
During an average follow-up of 8 months, 54% were free
of VT.77 Eighty-one percent of patients followed up for
more than 2 months had a greater than 75% reduction in
VT episodes. Procedure-related mortality was 2.7%. Other
complications included tamponade and stroke, each in 2.7%
and myocardial infarction in 0.7%. The Multicenter Thermo-
cool Ventricular Tachycardia Ablation Trial also enrolled 231
patients with recurrent VT in the setting of prior MI.83 VT
ablation used an open irrigation RF catheter guided by an
electroanatomic mapping using both entrainment mapping
and/or substrate mapping to guide ablation.83 Unmappable
VT was present in 69% of patients. During the 6-month
follow-up period, 51% had recurrent VT. The frequency of
VT was reduced with a >75% reduction in VT recurrence
in 67% of patients. Procedure mortality was 3% with 6 of
7 deaths related to uncontrollable VT, and one due to tam-
ponade with myocardial infarction. There were no strokes or
thromboembolic events. Nonfatal complications occurred in
7% of patients, including heart failure and vascular access
complications. Finally, the Substrate Mapping and Ablation
in Sinus Rhythm to Halt Ventricular Tachycardia (SMASH-
VT) multicenter study enrolled 128 patients with prior MI.182
All patients were receiving an initial ICD for VF, unstable VT,
or syncope with inducible VT.182 Patients were randomized
to substrate-based ablation versus a control group handled in
a routine fashion. There was no procedure mortality. During
an average follow-up of 23 months 33% of the control group
and only 12% of the ablation group received appropriate ICD
therapy for VT or VF.
VT Ablation in the Setting of Nonischemic
Cardiomyopathy
Approach to catheter ablation of VT
The substrate for VT typically surrounds the aortic and
mitral valve region and then extends apically.193 Frequently,
the substrate may be solely or predominantly intramural or
epicardial.35,194-196 Because of the frequent presence of an
epicardial substrate, some experienced operators use a simul-
taneous endocardial and epicardial mapping approach.71,197
Epicardially, the presence of a wide (>80 ms) split, and
late electrograms are required to identify an arrhythmogenic
substrate.196
Outcome of VT ablation
There are only a few single-center reports on acute out-
come of VT ablation with short-to-intermediate-term follow-
up in a relatively small numbers of patients in the setting
of nonischemic cardiomyopathy.35,126,198 Acute success in
eliminating inducible VT has varied from 56% to 74% with
VT recurrence of 42% to 75% with endocardial ablation.
Outcome appears to be somewhat improved with epicardial
ablation, but long-term follow-up in a large cohort of patients
has been lacking.35,196
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VT Ablation in the Setting of ARVC
It is critical to distinguish benign “idiopathic” focal VT
originating from the outflow tract or peritricuspid valve re-
gions of the right ventricle from VT associated with ARVC.
The diagnosis of ARVC is dependent on meeting Task Force
criteria.199,200 However, voltage mapping should also be used
to help establish the presence of a significant substrate ab-
normality consistent with the disease process.37,201 Mapping
of the right ventricular free wall especially in the perivalvu-
lar region may be technically challenging. Confirmation of
contact by demonstrating capture at low pacing output and
identification of signals that are not only small in ampli-
tude but frequently split or late can allow one to eliminate
small signals due to poor contact or intracavitary points and
help identify important targets for subsequent mapping and
ablation201 Of note, LV involvement is probably more fre-
quent than previously recognized.202 Moreover, data from
both pathological studies and recent reports on detailed
substrate mapping suggest that epicardial involvement is
more common than endocardial involvement with the disease
progression.203-205
Approach to catheter ablation
Because most VTs occur in the setting of a significant
substrate abnormality and are reentrant in mechanism, stan-
dard activation and entrainment mapping techniques can be
applied to identify a critical isthmus to target for ablation
for hemodynamically tolerated VT.23,31,116,206,207 Substrate-
based ablation techniques can be used for poorly tolerated,
unmappable VT.113 With irrigated catheters power titrated
to achieve an impedance drop of 10–15 ohms with a max-
imum temperature of 42 to 45◦C appears to allow for safe
lesion formation without steam pops. The endpoint of abla-
tion remains the noninducibility of monomorphic VT with
programmed stimulation through triple extrastimuli.
Outcome of VT ablation
No large prospective multicenter studies have been per-
formed to assess the value of endocardial ablative therapy
in reducing VT recurrences in this patient population. Sin-
gle center studies reporting on the outcome of 11 to 32 pa-
tients have in general been fairly consistent in their acute
and follow-up outcome results.36,42,201,208-214 The ability to
eliminate all inducible VT appears to range from 72% to
88%. Most patients have remained arrhythmia free during
long-term outcome with recurrence rates of 11–50% in part
related to duration of follow-up. To date only one study has
reported a very poor acute (46% noninducible) and then long-
term outcome (83% recurrence rate). This study included
a series of patients who did not undergo irrigated catheter
ablation and/or substrate-based ablation.212 The use of 3D
mapping systems was also limited in this report. Neverthe-
less, recurrence of VT after endocardial ablation does occur
and the requirement of antiarrhythmic drug therapy has been
commonly reported by some investigators.36
VT Ablation in the Setting of HCM
In HCM, 2 main factors may predispose to ventricu-
lar arrhythmias: the myocardial disarray and the increase
in left ventricular mass. The most common ventricular ar-
rhythmias observed with programmed electrical stimulation
include polymorphic VT and VF.215 On the other hand, clini-
cal sustained monomorphic VT in patients with HCM seems
uncommon but may be underestimated because of early de-
generation into VF.216 Patients with HCM and left ventricular
apical aneurysm represent an underrecognized but important
subgroup.
Approach to catheter ablation and outcome of VT ablation
The ablation strategy applied to a monomorphic VT in
patients with HCM is the same as in the setting of an old
myocardial infarction. It is important to mention that place-
ment of ablation catheter into the narrow neck of an apical
aneurysm can be technically challenging because the narrow
neck frequently obliterates during systole. Before maneuver-
ing the ablation catheter, it is advisable to perform an angiog-
raphy or other detailed echocardiographic or CT imaging of
the aneurysm and its neck. Such imaging may facilitate the
entrance into the aneurysm and may identify the presence of
a left ventricular thrombus that may cause the procedure to
be aborted.
Only a few cases have been reported in the literature on
the ablation of VT in HCM and essentially regard patients
with apical aneurysms treated with success.217
VT Ablation in the Setting of Congenital Heart Diseases
The occurrence of arrhythmia disturbances and, in par-
ticular, VT in the setting of congenital heart disease varies
according to the underlying anatomic defect and method of
surgical repair. Usually, the congenital malformations are se-
vere in 30% to 50% of cases, requiring surgical procedures
during early childhood. In the majority of cases, VT is a con-
sequence of prior corrective surgery, which can create the
ideal substrate for reentrant tachycardias due to the action
of patches and sutures in conjunction with hypertrophy and
fibrosis that create the necessary block and slow conduction
to promote reentry. Catheter ablation has become an indis-
pensable treatment option for this group of patients. The
majority of data are centered on repaired tetralogy of Fal-
lot that has a prevalence of VT between 3% and 14%218-222
and is associated with a risk of SD of 2% per decade of
follow-up.218 The pathophysiologic mechanism of VT is a
macroreentrant circuit in most cases, often involving narrow
conduction corridors defined of regions of surgical scars with
natural conduction barriers, such as the edge of a valve an-
nulus.223,224 In patients with operated tetralogy of Fallot and
VT, the macroreentry involves the RVOT, either at the site
of right anterior ventriculotomy or at the site of ventricular
septal defect patch.
Approach to catheter ablation
In the occurrence of sustained, hemodynamically toler-
ated VT, the principal electrophysiologic diagnostic maneu-
ver is the entrainment mapping. In patients with very fast,
poorly tolerated VT, the use of electroanatomical mapping
systems with voltage maps can be quite useful for detecting
areas of scars in the RV. In patients with repaired tetral-
ogy of Fallot, it could be important to create bidirectional
block of conduction between the tricuspidal annulus and the
RVOT patch. Creating a bidirectional block may allow ab-
lation in sinus rhythm without the need to map or ablate
during VT.225 Indeed, the isthmus between the anterior wall
of RVOT scar/patch and tricuspidal annulus is involved in
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roughly 75% of VT cases in patients with repaired tetralogy
of Fallot.226 In the literature, it is reported a success rate of
60% using electroanatomical mapping and/or conventional
techniques227,228 and of 50% using the noncontact mapping
in patients with VT after surgical repair of CHD.40
Outcome of VT ablation
Several case reports have been described in the last few
years, but unfortunately the follow-up is not uniform. In 2
small series,133 a total of 30 patients have been assembled,
including tetralogy of Fallot (17 cases), ventricular septal
defect (8 cases), and miscellaneous CHD (5 cases). Based
on these results, catheter ablation was acutely successful in
25 out 28 procedures (89%) and later VT recurrence was
documented in 5 cases (20%). Some of the recurrences could
have been related to the difficulty with RF current to create
a sufficient lesion in the often thick-walled chamber, like the
right ventricle in the tetralogy of Fallot.
VT Ablation in Other Clinical Settings
Chagas’ disease
VT in Chagas’ disease can have heterogeneous presen-
tations but occurs predominantly due to a reentrant mecha-
nism,229,230 sometimes clustered in electrical storms.231,232
Myocardial damage can occur in various areas of both ven-
tricles, but the inferolateral segment of the LV is the most
commonly involved site, with frequently observed wall mo-
tion abnormalities; apical aneurysmal formation and mitral
isthmus circuits are also common.193,233-236 In this areas,
endocardial mapping frequently depict fragmented late po-
tentials in sinus rhythm as well as continuous or diastolic
activity during VT. Histological analysis of those segments
has shown focal and diffuse fibrosis that is predominantly
subepicardial with nonuniform anisotropy of the surviving
fibers.
In a recent report on 138 patients,237 successful ablation
(defined as termination and noninducibility) was possible in
52% of patients. Importantly, only 2 major complications
were described (one abdominal cavity bleeding due to an
injured diaphragmatic vessel that required laparotomy and
another with coronary artery occlusion of a marginal branch
that caused non-Q-wave MI). Minor complications were rep-
resented by precordial distress, present in 29% and drainable
hemopericardium, present in 4.5% of cases.
Sarcoidosis
VTs in cardiac sarcoidosis are usually multiple reentrant
monomorphic VTs (scar-related), with either left or right
bundle branch morphology; low-amplitude and fragmented
potentials are recorded both in the endocardial and epicardial
regions of both ventricles.38,238 Two patterns of regional wall
motion abnormalities are frequently observed, involving the
basal free wall and the anteroapical septum.193 Catheter ab-
lation for VT is indicated in patients with frequent episodes
refractory to medical treatment. The reported success rates
ranges from 25%38 to 70%238 in a recently reported registry
and depends on the location of the reentrant circuit. The most
frequent circuit was found in the peritricuspid area.
Idiopathic LV aneurysms
Idiopathic left ventricular aneurysms are defined as
aneurysms of unknown etiology in the presence of normal
coronary arteries and absence of angina or history of myocar-
dial infarction; it is a rare condition frequently associated
with reentrant VTs.239,240 The LV aneurysms are smaller in
size and more often located at the posterior and/or inferior
wall, as opposed to postinfarction aneurysms that are often
located at the anterior wall.241,242
The inducibility of VT on EP study is high and the major-
ity has right bundle branch morphology. One of the largest
reported series of cases242 described an approach using ir-
rigated endocardial and epicardial catheter ablation of VT
from a left ventricular aneurysm in 4 patients. In that report,
75% were VT free during 31 months of follow-up using an
aggressive ablation approach. Other reports have shown that
RF catheter ablation could be performed around the neck as
well as inside the aneurysms.174-176
VT after cardiac surgery
Coronary artery bypass surgery usually has an antiarrhyth-
mic function in patients with VT or VF and an ischemic
substrate; there is, however, a selected group of patients
who either develop or aggravate ventricular arrhythmias af-
ter surgery. These may present as de novo VT occurring as
a consequence of surgery. One of the largest published se-
ries reported on 3,820 patients undergoing CABG in a single
center;243 12 patients (3%) developed de novo-sustained VT
a mean of 4.1 days after surgery. In most cases (92%), no
postoperative complication could explain the occurrence of
VT. De novo-sustained VT may also develop after corrective
valve surgery. A recent report by Eckart et al. demonstrated
that most of these VT appear to be scar-based and to have
a reentrant mechanism although bundle branch reentry must
be excluded.192 The scar is predominantly located around the
periaortic and mitral valve regions.
Mapping strategies as described for VT in the setting of
prior infarction can be used successfully to eliminate VT.
Ablation of VF
VF is usually initiated by a PVC during the vulnerable
period of cardiac repolarization. Ablation therapy for VF
has been recently described and increasingly reported. Most
cases of VF appear to originate from the His-Purkinje system,
although some cases have initiating events that are distinct
from the cardiac conduction system.244-249 Catheter abla-
tion of VF has been attempted in the following clinical set-
tings: postinfarction, LQTS, Brugada syndrome, infiltrative
cardiac amyloidosis, postcardiac surgery, and normal heart
(idiopathic VF).94,95,244-246,250-258
Approach to ablation
As mentioned before, the His-Purkinje system is the most
frequent site of initiation of VF. This adds some complex-
ity to the mapping process. Recording of the 12-lead ECG
of the triggering event can prove valuable in regionalizing
the origin of VT for more detailed mapping and an effort
to record such a trigger should be routine. During activa-
tion mapping of the PVC, special attention must be paid to
preceding sharp Purkinje-like signals. These may precede
the local ventricular activation during the PVC by tens of
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milliseconds. Mapping should be focused on the earliest ac-
tivation of this potential. One may see earliest Purkinje-like
potential activation in one spot and later activation of the
potential proximal and distal to that spot. With multipolar
catheters placed in the His position and down the left ven-
tricular septum, one can see the progression of the signal
through the conduction system with the His potential acti-
vating last. Sometimes, the potential may be seen with block
to the myocardium and not producing a PVC. Determining
the earliest potential is the key to successful ablation. Pace
mapping of the area of interest also requires special care.
The pacing amplitude output should be adjusted to attempt
to capture the His-Purkinje system alone; otherwise, the pace
mapping will appear dissimilar.
The Purkinje network is present on the superficial endo-
cardium and tends to respond to ablation quickly and without
the need for prolonged ablation times or high power. In cases
that a PVC is not spontaneous or inducible, ablation may
be performed along the distal LV septum with Purkinje-like
potentials in sinus rhythm, assuming the PVC has this mor-
phologic type. In patients with myocardial scar from previous
myocardial infarction, a high-density scar map should be per-
formed with careful attention to the border of the scar and
normal tissue, since the PVC may originate from this bor-
der. Along the border, one may see Purkinje-like potentials.
Further ablation may be performed in the area of arborized
Purkinje-like potentials and around the scar border. In pa-
tients with normal hearts and PVC that appear to be from
areas other than the His-Purkinje system, standard ablation
techniques of activation mapping of the earliest local elec-
trogram and pace mapping are typically employed.
Outcome of VF ablation
In general, patients who undergo ablation of VF are criti-
cally ill with storms of lethal arrhythmias, not responding to
medical therapy, and very likely to die without further inter-
vention. Patients with ICDs or in ICU settings have received
over 50 shocks in a 24-hour time period.94 Discussions of
ending life-sustaining measures are frequently initiated be-
fore ablation is offered, and many physicians do not realize
that ablation is a potential therapy. Understanding this, abla-
tion is frequently associated with success rates greater than
90%. Of course, this is a very select population of people that
survive to undergo ablation in the electrophysiology labora-
tory. Further study is needed to define the role of ablation in
cases that are not medically refractory.
Ablation of VT/VF in Patients without Structural Heart
Disease: Techniques and Results
Outflow Tract VT
Outflow tract VTs are not easily inducible at baseline
electrophysiologic testing and may require rapid burst pac-
ing and/or stimulation by isoproterenol. VT may become
incessant under stress or with isoproterenol, and cannot be
terminated by programmed electrical stimulation.259-262 VT
can be abolished with discrete RF lesions, demonstrating
that the cells responsible for the arrhythmias are contained
in a very small area.263 Catheter ablation represents a vi-
able alternate to medical therapy, especially in those patients
who do not respond or are intolerant to pharmacologic treat-
ment. In the absence of inducible tachycardia, pace mapping
is used to localize the discrete site of origin of focal idio-
pathic VT. Comparable efficacy between pace mapping and
activation mapping has been demonstrated.264 Subtle varia-
tions in QRS morphology of ventricular arrhythmia can be
observed, which may represent a wider endocardial “break-
through” with the arrhythmia focus located deeper in the
myocardium or in the epicardial layer.108,265 RF energy de-
livery, however, is associated with a high long-term success
rate (90–95%).266-269 In cases where the target VT or PVCs
are infrequently induced, the use of multielectrode or basket
catheters can be of value.268,270 In patients who had previ-
ously failed ablations, the use of electroanatomic mapping
systems, either nonfluoroscopic or noncontact systems, may
provide potential benefits in facilitating the procedure and
attaining a high acute success rate.98,109,270-271
Other variants of outflow tract VT include ventricular
arrhythmias arising from the aortic cusps, pulmonary artery,
and epicardial foci remote from the sinus of Valsalva. Limited
electropharmacologic data are available for these arrhyth-
mias. The potential for acute coronary artery occlusion is a
major risk consideration with catheter manipulation within
the aortic cusps. Coronary angiography or intracardiac ultra-
sound imaging has been used to define the anatomy (Fig. 6).
RF energy can be safely delivered in the aortic cusp and is
associated with a long-term efficacy (∼90%) in eliminating
aortic cusp VTs.44,272,273 The presence of double, delayed
potentials during sinus rhythm may be predictive of the site
of successful ablation.15
The idiopathic epicardial VTs commonly have an LBBB
pattern because the arrhythmia foci are located along the in-
terventricular veins near the septum, although right bundle
branch block QRS morphology can be observed.46,140 The
ventricular activation is usually slow with a slurred QRS on-
set that resembles a delta wave. The interval from the onset
of the QRS to the earliest maximal deflection in the precor-
dial leads is also prolonged, consistent with a delayed access
of the activation wave front to the endocardial Purkinje sys-
tem.46,58 Epicardial mapping and ablation via the epicardial
vein with coronary sinus cannulation, or direct access with
percutaneous pericardial catheterization can be successfully
performed.274
The pulmonary artery VTs appear to arise from remnants
of muscular sleeves that extend into the pulmonary arterial
trunk.58,274 This is supported by the presence of a sharp lo-
cal potential that precedes the onset of ventricular activation
during VT at the site of successful ablation.12,275,276 Dur-
ing sinus rhythm, an atrial potential is frequently recorded
(>58%) along with a diminished, low-amplitude local ven-
tricular potential at the successful ablation site.
Despite careful mapping and use of sophisticated tech-
niques, identifying the precise location of arrhythmias in
outflow tract VT may be difficult because of the complex
anatomic relationship and the proximity of various struc-
tures from the venous and arterial circulations. In addition
to electroanatomic mapping, the use of intracardiac or trans-
esophageal ultrasound to identify anatomic landmarks and
catheter contact may facilitate ablation of idiopathic outflow
tract VT.277
A stepwise systematic approach, from endocardial map-
ping and then epicardial mapping up to 6 anatomic ac-
cesses (RVOT, LVOT, coronary sinus, aortic cusp, pulmonary
artery, and LV epicardium) can lead to successful RF catheter
ablation.278
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Figure 6. Mapping and ablation of idio-
pathic ventricular tachycardia originat-
ing from the left aortic cusp. Fluoroscopic
images of the ablation catheter located at
the aortic cusp in right anterior oblique
and left anterior oblique views. Simulta-
neous coronary angiography is performed
to visualize the left main artery to assess
its distance from the ablation site.
Annular VT
Idiopathic ventricular arrhythmias can also arise in prox-
imity to the valvular annuli. Focal VT from the mitral annu-
lus accounted for 5% of the idiopathic VT in one series.279
The arrhythmia typically has a right bundle branch block
morphology and may originate from different portions of
the mitral annulus (anterolateral, posterior, posteroseptal),
resulting in different QRS axis.52 Idiopathic ventricular ar-
rhythmias originating from tricuspid annulus have also been
described recently.51 The predominant (74%) site of origin is
located at the septal portion of the tricuspid annulus with the
remaining arrhythmias arising from the annular-free wall.
The detailed origin can be determined by ECG analysis.
Repetitive monomorphic right VT originating near the His
bundle may be recognized as a specific entity with distinctive
ECG characteristics.280 Recognition of this arrhythmia is im-
portant because of its unique location and the potential risk
associated with catheter ablation. Knowledge of the char-
acteristic QRS morphology will facilitate catheter mapping
and successful ablation. The use of a supporting sheath to as-
sure catheter stability, careful RF energy power/temperature
titration, and cryoablation may improve the outcome and
minimize complication.280,281
Verapamil-Sensitive Fascicular VT
This form of VT has a right bundle branch block with
left axis deviation, can be induced with atrial pacing, occurs
in patients without structural heart disease and is verapamil
sensitive.281-283 The mechanism is reentry within the Purk-
inje fibers of the left ventricular septum, most often arising
from the left posterior fascicle.92,93,262,284 Less often, the
reentry is located in fibers distal to the anterior fascicle or
may arise from fascicular locations high in the septum and
has a relatively narrow right bundle branch block pattern and
right inferior axis deviation285 Fascicular tachycardia usually
presents in patients between 15 and 40 years of age. Although
ILVT can occur at rest, it is sensitive to catecholamines and
often occurs during exercise, postexercise, or emotional dis-
tress. RF catheter ablation can be performed successfully
(>80%) from the VT exit site (at the site of earliest ven-
tricular activation), or the zone of slow conduction where
a Purkinje potential was recorded in diastole during VT.286
Critical sites of the reentrant circuit can also be identified
by the earliest retrograde Purkinje network activation during
sinus rhythm.93 For patients with noninducible or nonsus-
tained fascicular VT, a linear ablation strategy (mean 1.7
cm) perpendicular to the long axis of the ventricle, targeting
the midinferior septum marked by the presence of Purkinje
potentials in sinus rhythm and the best pace-map match of
the VT, has been shown to be safe and effective for VT
control.286
Idiopathic VF
Recent work has demonstrated that the Purkinje network
is critical in the triggering and maintenance of VF in animal
experiments and patients.244,287,288 Catheter ablation target-
ing the PVC or Purkinje potentials responsible for triggering
VF or both has been shown to be both possible and effica-
cious in a number of conditions, ranging from the Brugada
syndrome, ischemic VF, to idiopathic VF. In order to map
and then ablate VF, it is essential that there is accurate docu-
mentation of the triggering PVC with a 12-lead ECG. Due to
the unpredictable nature of triggering beats, the optimal time
for ablation is often in occasion of an electrical storm when
the PVC tends to be frequent. The source of triggers is local-
ized by the earliest electrogram relative to the onset of the
ectopic QRS complex. An initial sharp potential (<10 ms in
duration) preceding the ventricular electrogram during sinus
rhythm as well as during PVC indicates the latter originates
from the Purkinje system, whereas its absence at the site of
earliest activation indicates an origin from ventricular mus-
cle. Great care should be taken to avoid mechanical bumping
of the right bundle branch while mapping as this would mask
ipsilateral Purkinje activation during sinus rhythm.
Myocardial ectopics triggering VF
RVOT is the most common site of origin of myocardial
ectopics triggering malignant monomorphic or polymorphic
VT that rapidly degenerates into VF in structurally normal
hearts.289 The type of ablation is essentially no different to
ablation of idiopathic RVOT ectopy or VT with a discrete
and usually solitary focus located in a well-defined anatomic
region. The coupling interval is significantly longer for ec-
topics of an RVOT origin compared with short-coupled Purk-
inje origin (mean coupling interval of 300 ms). Furthermore,
the number of ectopics to guide mapping is usually very high
in contrast to the capricious occurrence of ectopics in other
patients with idiopathic VF.
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Purkinje-triggered idiopathic VF
Anatomically, the Purkinje system is a small fraction of
the myocardial mass, consisting of specialized fibers insu-
lated from the underlying ventricular myocardium until their
peripheral arborization into muscle. Narrow PVCs are cer-
tainly strong ECG markers that can be used to noninvasively
identify Purkinje origin. PVC with a positive morphology in
V1 indicates left ventricular origin and PVC with negative
morphology in V1 indicates right ventricular origin.
Endocardial mapping and ablation
The use of polygraph system at high sampling
rate (>2 kHz) and high gain amplification (commonly
1 mm = 0.1 mV) is optimal in order to clearly identify
Purkinje potentials. The Purkinje sources are localized to a
limited part of the anterior right ventricle or in a wider re-
gion of the lower half of the septum in the left ventricle244
Recording of stable Purkinje activity is more difficult in the
right ventricle. During PVC, the earliest Purkinje potential
precedes the local muscle activation by a conduction interval
of 38 ± 28 ms, with a greater precocity in the left than in
the right ventricle (46 ± 29 vs 19 ± 10 ms).244 At the same
site, differing conduction times are associated with varying
morphologies suggesting either changes in ventricular acti-
vation route or origin from another part of Purkinje system.
During sinus rhythm, however, the Purkinje potential closely
precedes the ventricular muscle activity by 11 ± 5 ms in-
dicating distal arborization.244 Ablation of Purkinje beats
frequently produces temporary exacerbation of arrhythmia
(including VF) followed by a disappearance of PVC. Differ-
ent morphologies are progressively eliminated by ablation at
multiple sites with early Purkinje potential, using a mean of
9± 5 (range 2 to 19) RF applications.244 Local electrograms
show the abolition of the local Purkinje potential and slight
delay in the occurrence of the local ventricular electrogram.
There have been a multicenter study and a number of case
reports of successful VF ablation for patients with idiopathic
VF.244,246,247,249,290,291
Acute and Periprocedural Complications
In idiopathic VT, serious complications range from 0%
to 4%.11,176,263,280,292-294 Death was reported in one case as
following right ventricular perforation.267 In patients with
VT associated with structural heart disease, catheter ablation
appears associated with a greater risk of complications. In
2 large multicenter studies, major procedural complications
ranged from 3.8% to 8%.77,188 Death was reported in 2.7%
of cases.77
Thromboembolic Events
The rate of thromboembolic events is 2.8% for the ablation
of ventricular arrhythmias.188,295,296 The higher incidence of
thromboembolic events in the VT patients, compared with
patients with supraventricular arrhythmias, might be related
to the site of ablation (frequently the left ventricle), longer
procedure time, multiple RF current applications, preexisting
atherosclerotic aortic disease, and the possibility of preexist-
ing thrombus that was not detected by transthoracic echocar-
diography. To minimize the occurrence of thromboembolic
complications, aspirin is prescribed (81 mg to 325 mg) just
before the procedure and an optimal dose of heparin in-
fused for systemic anticoagulation (see above, pre- and in-
traablation patient management). For patients with VT of
epicardial origin, heparin is started after pericardial punc-
ture. After ablation, prolonged anticoagulation may be re-
quired in some patients, as thromboembolic complications
can occur even 3 months after ablation.297,298 Second, it is
important to monitor the change in the impedance of the
ablation catheter during delivery of RF energy. A sudden
increase in the impedance of more than 20 ohms is as-
sociated with coagulum formation. Transthoracic echocar-
diography and transesophageal echocardiography should be
used for routine screening of mural thrombus in the cardiac
chamber, especially for ischemic VT with left ventricular
dysfunction. For patients with severe atherosclerotic aortic
disease, catheter access via transseptal approach should be
considered to avoid thromboembolic complications. To make
large transmural lesions without unfavorable heating injury
and thromboembolic complications, a cooled RF ablation
catheter is preferable.
Perforation and Tamponade
Incidence of cardiac tamponade or hemopericardium re-
quiring immediate drainage is 0.4–2.7%77,83 in catheter abla-
tion for VT. The complication can develop during transseptal
puncture, catheter manipulation, or ablation. Perforation of
the left ventricle by the ablation catheter is uncommon be-
cause the left ventricle is thicker; however, the thin-walled
right ventricle (particularly near the apex) may be more vul-
nerable to perforation by an ablation or pacing catheter. For
prevention of right ventricle perforation, a power setting not
exceeding 40 W and careful monitoring of the impedance are
required. While percutaneous drainage of the hemorrhagic
effusion is usually sufficient, spontaneous closure of the per-
foration may not occur, and subsequent surgical intervention
may be required. During urgent pericardiocentesis, retransfu-
sion of aspirated blood has the risk of systemic inflammatory
response.
Valvular Complications
The incidence of valvular injury is reported to be 1.9% and
is often minor.299 Damage to the mitral valve can result from
inadvertent manipulation across the valve or from an injury
to the papillary muscles or chorda tendinae during or after
ablation of VT. In patients with VT originated from aortic
cusp, damage to the aortic valve could occur. To avoid these
valvular complications, it is important to make sure there is
no entrapment of the ablation catheter in these structures and
to watch the change in impedance during RF delivery.
Condution System Complications
The rate of AV block or newly developed bundle branch
block after VT ablation is known to be less than 1–2%.77,300
For patients with preexisting LBBB and bundle branch reen-
try tachycardia, ablation of right bundle may cause complete
AV block (0% to 30%);301-304 however, a compensating con-
duction may occur through the left bundle, suggesting that
right bundle ablation may be safe in the majority of patients
with baseline LBBB. Ablation of the left bundle has been
proposed as ideal, but this technique is difficult to perform
and usually requires application of multiple lesions. For ab-
lation of left posterior fascicular VT, ablation of the apical
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third of the inferior septum is preferred to avoid producing
an LBBB or AV block.
Worsened Heart Failure or Left Ventricular Function
In patients with significant heart disease, ablation of VT
can involve multiple applications and long lines of RF le-
sions in already deteriorated left ventricular function. Un-
fortunately, few data are available to this regard. In a small
series, Marchlinski et al. reported that none of their 6 pa-
tients in whom left ventricular EF was measured before
(mean 24 ± 6%) and after (mean 23 ± 9%) ablation suf-
fered deterioration greater than 5%.113 In another series of
62 patients, Khan et al. reported that multiple RF ablation
lesions confined to infarct regions did not measurably affect
LV function.305
Coronary Artery Injury and Complications
Thermal injury to the coronary arteries has been described
during the ablation of VT.306 Coronary artery stenosis has
been found to be a late consequence (12–24 months) of ves-
sel trauma or vasospasm. As the use of catheter ablation is
increasing, especially in children and young adults, a de-
tailed understanding of coronary artery anatomy is critical
for safe ablation. Coronary angiography or ICE may be con-
sidered when ablation sites are in the high-septal aspect of
the RVOT177 or in the aortic cusps. When the distance be-
tween the coronary arteries and the ablation sites is found to
be less than 5 mm, cryoablation or 4-mm tip catheters may
be considered, in order to avoid short- and long-term damage
to the coronary arteries. The safety and efficacy of epicardial
RF ablation, especially in the vicinity of the coronary artery,
remain unclear. In order to avoid coronary artery injury, coro-
nary angiography is usually performed to visualize the re-
lationship between RF target sites. This approach, however,
requires frequent coronary contrast injections in different
projections. Recently, some authors have suggested a dif-
ferent approach based on the fusion of CT and endocardial
and epicardial electroanatomical mapping data to improve
visualization of the catheter tip in relation to the epicardial
coronary arteries.307
Vascular Access Complications
Aortic atheroembolism
The formation of multiple cholesterol emboli is a rare but
serious complication. It is caused by cholesterol crystals that
embolize and block small arteries. No specific treatment is
available, and morbidity and mortality are high. It tends to be
associated with difficulty in manipulation of catheters within
a severely diseased aorta. A common feature is leg pain
with livido reticularis despite palpable pulses. Confusion,
renal failure, and death ultimately ensue.308 In patients with
severe aorta disease, it might be reasonable to use a long
vascular sheath to advance the ablation catheter directly into
the left ventricle. Alternatively, a transseptal approach could
be considered.
Pseudoaneurysm, local hematoma, and arterovenous fistula
All interventional procedures carry a risk of local vas-
cular complications, such as pseudoaneurysm, hematoma,
and arterovenous fistula. The incidence of these complica-
tions is particularly related to the type of procedure per-
formed (right- or left-side catheterization). In the Multicen-
tre European Radiofrequency Survey (MERFS), the inci-
dence of major bleeding at the puncture site ranged between
0.23% and 0.63%.296 Van Hare et al. reported a 4% inci-
dence of hematoma.309 Kelm et al. found that almost 1%
suffered femoral arterovenous fistula.310 One-third of ia-
trogenic arterovenous fistula closes spontaneously within 1
year. Cardiac volume overload and limb damage are highly
unlikely with arterovenous fistula persistence. Thus, con-
servative management for at least 1 year seems to be jus-
tified.310 Femoral pseudoaneurysm is a common complica-
tion, and occurs in up to 6% of diagnostic or therapeutic
catheterization procedures. Spontaneous closure is the rule
for small pseudoaneurysms. Large and complex pseudoa-
neurysms need treatment to prevent complications, such as
embolization.311 Manual compression repair, with or with-
out ultrasound guidance, remains first-line treatment. A sur-
gical approach is indicated in selected cases. New therapies
have recently emerged that are noninvasive and suitable for
most patients, even those who are critically ill. Nonsurgical
treatment options in addition to compression therapy include
endoprosthesis placement, coil embolization, and percuta-
neous collagen and thrombin injection. The prophylactic use
of anticoagulation therapy after the ablation procedure could
increase the risk of developing vascular complications. An-
other important risk factor for this complication is the size of
the sheaths used to introduce the catheters into the vessel.
Complications Associated with Epicardial
Mapping/Ablation
Access
Compared with endocardial approach, epicardial ablation
has some additional risks. Some degree of pericardial bleed-
ing is recognized in approximately 30% of cases,312 mostly
due to the unintentional right ventricular puncture or lesion of
pericardial vessels. Bleeding usually resolves with repeated
aspiration of the pericardial space,313 and rarely requires sur-
gical intervention.133 To prevent the laceration, the sheath
should never be left without a catheter inside. Puncture of
a subdiaphragmatic vessel causing intraabdominal bleeding
has been reported and can potentially require surgery.237,312
Anterior access may have less risk of intraabdominal bleed-
ing, including liver puncture, compared with the inferior ac-
cess.
Mapping/ablation
RF injury to coronary arteries can cause acute throm-
bosis.237 In addition, severe coronary artery spasm has been
reported during epicardial mapping.139 The long-term conse-
quences (beyond 1–3 months) of ablation near the coronary
arteries are unknown. Injury of the left phrenic nerve has
been reported.314 Proximity to the nerve can be detected by
pacing with high stimulus strength.35 To prevent the phrenic
nerve damage, moving the nerve away from the myocardium
by injection of air into the pericardium, or placement of a
balloon catheter between the ablation site and nerve has been
reported.315,316
Postprocedure
Symptoms of pericarditis can be observed in about 30%
of cases after the procedure.237 Pericardial instillation of a
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glucocorticoid following the procedure has been shown to
reduce inflammation,317 and is performed routinely in some
centers.
Post-VT Ablation Follow-Up Management
Follow-up and postablation management of patients after
catheter ablation for VT is largely determined by the type
of VT being ablated. For patients with structurally normal
hearts and idiopathic VT, follow-up can be straightforward
and similar to the follow-up after an ablation procedure for a
supraventricular tachycardia. However, in patients with struc-
tural heart disease, follow-up management can be complex
and depends on the nature of the underlying disease. In ad-
dition to proper surveillance for procedural complications
and outcome, management also includes the possibility of
ongoing antiarrhythmic drug therapy and optimization of
medical therapy to control the underlying heart disease. At
present, there are no guidelines or a widely accepted con-
sensus statement for the postablation management of VT
patients. Follow-up management should focus on: (1) under-
standing and improving long-term prognosis and (2) medical
therapy and ongoing monitoring.
Prognosis Post-VT Ablation
Knowledge of the prognosis post-VT ablation is impor-
tant to understand the postablation management priorities for
these patients. In case of idiopathic VT without detectable
structural heart disease, such as VT arising from the RVOT,
aortic cusp, or left ventricular fascicles, the long-term prog-
nosis is in general excellent, with or without arrhythmia
elimination.269 Catheter ablation is primarily performed to
limit symptoms and to improve quality of life, with low
long-term morbidity or mortality risk. In patients with struc-
tural heart disease, long-term prognosis is often worse com-
pared with the patients without detectable structural heart
disease. Because of the progressive nature of most cardiomy-
opathies, recurrence of (non) ablated VT and/or death from
nonarrhythmic cardiac causes (such as pump failure) become
more prevalent over time. After VT ablation in patients with
structural heart disease, the arrhythmic outcome over 1–5
years follow-up seems to be directly correlated to the de-
gree of acute procedural success.74,77-83,191 Acute outcomes
may be defined as “total,” or “partial success,” or “failure.”
Unfortunately, the literature has used varying definitions of
“clinical VT” (especially when 12-lead documentation was
not available) and varying stimulation protocols (3–5 ex-
trastimuli), stressing the necessity to standardize definitions
of success.318 However, regardless the definitions used, stud-
ies have reported the best results in “total” success patients
with VT recurrence rates as low as 4–16% over 1–2 years’
follow-up. “Partial” success patients have an intermediate
recurrence rate of 40–65%, while “failures” have recurrence
rates in excess of 90–99%.79,83,191 The mortality rate in VT
patients with structural heart disease is also substantial with
reported 1-year mortality rates to be 16–18% with 70–75% of
those deaths attributable to a cardiac cause.83,191 Importantly,
53–65% of these cardiac deaths are due to a nonarrhythmic
cause, indicating the importance of optimizing management
of the underlying heart disease. Interestingly, the rate of
death from nonarrhythmic cause is also directly related to
acute procedural success, with the highest mortality rates in
patients where VT could not be successfully or totally elimi-
nated.83 Finally, the occurrence of an electrical storm (one of
the most common reasons for VT ablation) is a strong pre-
dictor of increased long-term mortality (about 25–30% over
2 years).319
Medical Therapy Post-VT Ablation
For patients with idiopathic VT and no detectable struc-
tural heart disease, medical management is similar to that for
reentrant supraventricular tachycardia. Since elimination of
all medication is often the goal of ablative therapy in this
population, immediate discontinuation of drugs postablation
is the best strategy to allow for monitoring of recurrence.
In patients with a VT recurrence, the decision to pursue re-
peat ablation, or restart medication will be an individualized
decision. Antiplatelet therapy with aspirin 80–325 mg/day
for 4–6 weeks postablation can be considered for idiopathic
VT patients who have had left-sided ablations or extensive
ablation lesions to minimize the risk of thrombus, although
there is little evidence that is a clinically relevant problem
or that such therapy would prevent it. In VT ablation pa-
tients with structural heart disease, medical therapy can be
subdivided into 4 major headings: antiarrhythmics, antico-
agulation, beta-blockade, and heart failure management.
Antiarrhythmics
Antiarrhythmic drug therapy is often continued in most
patients’ post-VT ablation. In 2 recent reports, 70–90% of
patients were maintained on their preablation antiarrhythmic
drug therapy, with only about 25–30% of these patients hav-
ing their doses reduced.79,82,83,191 In contrast to the atrial fib-
rillation population, freedom from antiarrhythmic drugs may
not be a reasonable goal given the complexity and progressive
nature of the VT substrate. Even after apparently successful
procedures, recurrence rates within 2 years are as high as 10–
15%.74,83,191 Furthermore, many of these patients are taking
on antiarrhythmics for concomitant reasons (such as AF) and,
thus, total elimination may not be feasible. Dose reduction
may be an important goal, particularly for amiodarone for
which the incidence of side effects is closely related to daily
dose.320 In various trials, dose reduction of amiodarone is
reported and doses may be reduced in a progressive manner
starting within the first 3–6 months postablation.191 There
are, of course, some patients where ablation is pursued as an
alternative to antiarrhythmics, particularly where drugs may
be causing unacceptable side effects. In these patients, drugs
may be discontinued postablation, probably after a minimum
of 3 months follow-up to assess clinical outcome.
Anticoagulation
Within the first 3 months postablation, particularly on
the left side, there may be a risk of systemic thromboem-
bolism, particularly if extensive ablation lesions were ap-
plied. However, there is no absolute proof of this, since only
2 TIAs were reported out of 390 patients (0.5%) accumulated
from 3 recent, large-scale reports83,182,191 using antiplatelet
or no anticoagulant therapy only. Furthermore, most VT pa-
tients with structural heart disease are already receiving some
form of antithrombotic or anticoagulant therapy, such as an-
tiplatelet therapy in the coronary disease patients, or war-
farin for patients with DCM and/or atrial fibrillation. Based
on consensus opinion, and on postablation procedures from
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published data, it is recommended that a minimum of aspirin
80–325 mg/day be used for 3 months postablation in patients
who have had left-sided or extensive ablations. Warfarin may
be used for higher risk patients (documented thrombus, pre-
vious stroke/TIA, atrial fibrillation, severe left ventricular
dysfunction, etc.). Surveillance with echocardiography for
thrombus is discussed later.
Beta-blockade
Beta-blockers should be maximized in most patients post-
VT ablation with structural heart disease. Effective beta-
blockade has been shown to reduce both arrhythmic and
nonarrhythmic death in patients with left ventricular dys-
function.321 Furthermore, concomitant use of beta-blockers
with other antiarrhythmic agents is superior to the use of ei-
ther agent in isolation, as shown by the OPTIC trial.322 Even
in patients receiving low-dose sotalol, there is not much beta-
blocker effect in doses of 80 mg BID or less. Thus, addition
of a traditional beta-blocker in combination with low-dose
sotalol may be useful.
Other heart failure therapy
Many VT ablation patients have coexisting cardiomyopa-
thy and, given the high rate of death from heart failure over
the first 1–5 years postablation (see above), appropriate long-
term heart function management must be optimized. Keep in
mind that therapy shown to reduce mortality in HF patients,
including statins and fish oil,323-326 should be used whenever
possible. Acutely, attention must be paid to volume status,
particularly since patients are lying flat for prolonged periods,
and often, an open-irrigated tip ablation catheter is used that
can add 1–2 L of volume acutely to the patient. Significant
volume overload requiring prolonged admission can occur in
as many as 1–2% of patients post-VT ablation. Thus, diuretic
doses may need to be increased in the days postablation to
achieve a baseline fluid status. Electrolytes should also be
closely monitored and corrected in the first few days.
Monitoring Post-VT Ablation
For patients with idiopathic VT and no structural heart dis-
ease, ablation is usually undertaken for symptomatic arrhyth-
mias. Following a successful ablation procedure, patients
should be seen at the outpatient clinic at regular intervals up
to 1 year following the initial procedure. Follow-up should in-
clude 24–48-hour Holter monitoring at regular intervals. For
patients with little or no symptoms or patients with infrequent
arrhythmia episodes prior to ablation, prolonged monitoring
with loop recorders, or transtelephonic monitoring should be
considered. Exercise stress testing may be useful for patients
with a history of exercise-induced VT’s. Echo monitoring at
regular intervals to assess LV/RV function should be con-
sidered in postablation patients with a history of suspected
PVC-induced cardiomyopathy. After an unsuccessful abla-
tion procedure it is advised to wait at least 3 months before
scheduling a repeat ablation procedure in order to assess the
burden of recurrent arrhythmias. In VT ablation patients with
structural heart disease, monitoring recommendations may
be grouped as follows:
ICD
Most patients with structural heart disease and VT un-
dergoing ablation either already have an ICD or will get an
ICD implanted after the procedure. If an ICD is present, ICD
functions should be checked immediately and 3 months after
ablation to detect any device-lead malfunctions, such as lead
dislodgement/damage, change in sensing or pacing thresh-
olds, or device infection. Thereafter ICDs should be checked
every 3–6 months. Given the monitoring capabilities of ICDs,
they are ideal to monitor arrhythmia recurrences. However,
documentation of every PVC or nonsustained VT episode
may not be clinically useful or relevant. The suggestion from
the United States Food and Drug Administration (FDA) in
1999 was to document only those VTs requiring therapy (an-
titachycardia pacing or shock) or nonsustained VT episodes
lasting >20 seconds as clinically relevant.327 The FDA guide-
lines suggested a minimum of 6 months follow-up post-VT
ablation for clinical trials, but a minimum of 1 year seems
reasonable. Postablation programming should be performed
as per emerging guidelines to minimize ICD shock deliv-
ery, such as using higher cutoff rates for VT and VF zones,
extending detection limits, and aggressive use of antitachy-
cardia pacing even for faster VTs. Monitor zones at lower
rates may be programmed to look for slower VTs that may
have been targeted during ablation, but do not necessarily
warrant shock therapy.
Other rhythm monitoring
For ICD patients, other forms of rhythm monitoring are
probably not warranted beyond standard ECGs acquired at
each clinical visit. For patients without ICDs, intermittent
ECG and 24–48-hour Holter monitoring should supplement
symptom monitoring, with each clinical visit at 3 and 6
months and every 6 months thereafter. Loop recorders and/or
transtelephonic monitoring may increase the yield of asymp-
tomatic VT detection, as suggested by the atrial fibrillation
literature, but whether such VT would be clinically relevant
or not in this population is not well known.
Echoardiography
At a minimum, echo should be performed within 24–48
hours preablation and within 1-week postablation to look
for thrombus or deterioration in ventricular function. Re-
peat echo should be considered at 3 months postablation
for those patients who have documented thrombus and have
been given warfarin to study if the thrombus has resolved.
The 3-month echo is also useful to document changes in
ventricular function postablation. For some patients, such as
those with PVC-induced cardiomyopathy, it may take at least
3 months to detect improvement in left ventricular function.
Conversely, in severe cardiomyopathy patients, left ventricu-
lar function may deteriorate if extensive ablation is performed
in viable tissue.
Repeat Ablation
The decision and timing of performing a repeat VT ab-
lation will be dependent on the context and urgency of the
clinical situation. If possible, in line with the FDA guide-
lines one should wait for at least 1 week following ablation
to assess possible procedure-related complications and to
study the recurrence rate.327 However, in case of frequent
recurrences or even an electrical storm the repeat procedure
should be scheduled as soon as possible. Other indications
for repeat ablation would include failure of the first proce-
dure, ongoing delivery of ICD therapy, ongoing high burden
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of ventricular arrhythmias, or inability to stop antiarrhythmic
medication that is causing side effects.
Surgical Ablation
The rationale of surgery for VT is based on either abla-
tion or exclusion of the arrhythmogenic substrate responsible
for the arrhythmia.328 Therapeutic targets of the procedure
are the earliest activation site during VT and the areas of
low and/or delayed and/or fractionated potentials during di-
astole.329-331
Although very effective, surgical ablation of VT is as-
sociated with significant mortality and morbidity.332 There-
fore, at present it should be considered only in selected pa-
tients, when other less invasive therapeutic interventions have
failed.
Surgical Indications and Procedure
Surgery can be considered under the following conditions:
(1) low-risk patient, with a discrete scar, preserved left ven-
tricular function, and persistence of problematic monomor-
phic sustained VT after failed catheter ablation; (2) life-
threatening electric storm after failed catheter ablation, as
a life-saving procedure, but only after careful consideration
of the patient’s left ventricular anatomy and function and
the severity of comorbidity; and (3) after attempted catheter
ablation, when there is good evidence that the arrhythmo-
genic targets are epicardial and there is contraindication or
difficulty to the transthoracic percutaneous access.
Patient should have an extensive preoperative work-up
with, in particular, an electrophysiologic study to document
the number, site of origin of various VT morphologies, low-
amplitude mapping to delineate the area of scar tissue with
special attention to areas outside the main endocardial scar,
as well as attempts of an RF catheter ablation. The surgi-
cal team must comprise a well-experienced group of experts
in surgery and electrophysiology ready to demonstrate an
excellent teamwork. Intraoperative electrophysiologic study
should include all sophisticated mapping, catheter and surgi-
cal techniques. Before entering the left ventricular aneurysm,
comprehensive epicardial mapping should be performed to
identify early epicardial breakthroughs during tachycardia.
Ablation should be guided by electrophysiological mapping
during sinus rhythm and VT, as well as by cardiac pathology.
All areas of endocardial fibrosis should be ablated or ex-
cluded. The surgery can be performed on the arrested heart
or beating heart. Closure of the LV can use LV remodeling
techniques, with which the surgeon is comfortable.
Indications to VT/VF Ablation and Hybrid Therapy
The indications for catheter ablation in general, and for
VT/VF ablation in particular, have evolved rapidly since the
first application in humans with ongoing improvement of
technology and increase in experience. However, as with
other technology-based approaches, progress is rapid, which,
among other reasons, has prevented the performance of large
randomized multicenter clinical trials with long recruitment
periods during which technology usually will have changed.
Therefore, almost all indications even when considered as
strong (class I and II a) have a low level of evidence.
Indications for Ablation of Idiopathic Right Venticle/Left
Ventricle VT/VF
RVOT/LVOT VT
These arrhythmias are typically benign and rarely cause
SD. The success rate for ablating RVOT/LVOT VT is high,
from greater than 80% to 95%.278,280,289,333,334 However,
long-term late recurrences have been reported to be rela-
tively common.294 Of note, with more recent sophisticated
mapping and ablation approaches, the serious complication
of cardiac perforation and tamponade during ablation in this
area has been reported to be <1%.
VT originating from the aortic sinus of Valsalva
The origin of these unusual forms of VT is most fre-
quently from the left coronary cusp but can also be found in
the right coronary cusp and the noncoronary cusp.272,335 Ab-
lation success rates from very experienced laboratories have
been high, greater than 80%, with minimal complications.
However, a dire consequence can be acute occlusion of the
coronary artery, which has been reported.
Fascicular left VT
Verapamil-sensitive idiopathic left VT occurs primarily
due to reentry involving the fascicles of the left bundle
branch.42,103,336 RF ablation is highly effective (>80%) and
should be considered in patients in whom medical therapy is
unsuccessful or poorly tolerated.
Other idiopathic VT
Ablation has been attempted with success also in other
forms of idiopathic VT, such as mitral and tricuspidal annu-
lar VT, VT originating from pulmonary artery or PAP, and
epicardial VT.46,51,52,274,275,278,279,337 However, the ablation
in these particular sites may bring a higher risk of complica-
tions.
Idiopathic VF
Catheter ablation has been also proposed in selected pa-
tients with idiopathic VF, whose arrhythmia is consistently
triggered by PVC originating from Purkinje fibers.338,339
However, long-term results from larger clinical trials are re-
quired before this indication becomes routine recommenda-
tion in clinical practice.
Recommendations
The indications of ablation for idiopathic right ventri-
cle/left ventricle VT/VF are summarized in Table 3.
Indications for Ablation of Nonischemic VT/VF
In general, VT and VF complicating nonischemic struc-
tural heart disease are treated with ICD. Catheter ablation
is considered adjunctive or palliative therapy most of the
time. Catheter ablation is recommended for patients with an
ICD who are receiving multiple shocks as a result of sus-
tained VT/VF that is not manageable by reprogramming or
optimization of drug therapy. In patients with bundle branch
reentry VT, catheter ablation may be considered as standard
therapy. In patients at low risk of SD and sustained monomor-
phic VT, catheter ablation is also recommended when drug
therapy is not effective, not tolerated, or not preferred. In
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TABLE 3
Indications of Ablation for Idiopathic Right Ventricle/Left Ventricle VT
Class I:
1. Symptomatic VT/PVC of right ventricular origin unresponsive to
medical therapy with beta-blockers and calcium channel-blockers
2. Symptomatic VT/PVC of left ventricular fascicular or endocardial
origin remote from aortic sinus of Valsalva, unresponsive to medical
therapy with beta-blockers and calcium channel-blockers
3. Symptomatic or asymptomatic VT/PVC of right ventricular or left
ventricular origin thought to be causing cardiomyopathy and
unresponsive to medical therapy
Class II a:
1. Asymptomatic sustained VT of right ventricular origin unresponsive
to medical therapy
Class II b:
1. Symptomatic VT/PVC originating from uncommon left ventricular
sites (aortic sinus of Valsalva, epicardium) that are unresponsive to
medical therapy including class I/III agents
2. Asymptomatic sustained VT of left ventricular origin unresponsive
to medical therapy
Class III:
1. Asymptomatic PVC of right or left ventricular origin not thought to
be causing cardiomyopathy
PVC = premature ventricular contractions; VT = ventricular tachycardia.
patients at low risk of SD and symptomatic nonsustained
monomorphic VT, catheter ablation may be useful as an al-
ternate to medical treatment. The role of prophylactic abla-
tion of VT/VF for prevention of ICD therapy in nonischemic
VT/VF has not been assessed yet.
Considerations regarding the different etiologies
responsible for nonischemic VT/VF
In idiopathic DCM and Chagas’ disease, the origin of
the arrhythmia is often epicardial (in more than 25–30% of
cases);35,193 this may complicate the procedure, since an epi-
cardial approach is frequently required with all the risks that
it brings. In patients with ARVC, the role of catheter abla-
tion is questionable as primary treatment strategy, in view of
the diffuse and progressive character of the disease.212 This
appears to be also the case in Chagas’ disease. In cardiac sar-
coidosis, catheter ablation is likely to improve prognosis only
in patients with still-preserved left ventricular function.38,238
In HCM, the role of catheter ablation is usually limited, with
the only exception of patients with an apical aneurysm.339 In
patients with Wolff-Parkinson-White syndrome, catheter ab-
lation of the accessory pathway is clearly indicated in cases of
atrial fibrillation with rapid preexcited ventricular response
causing VF, or in cases with very short (<240 ms) refractory
period of the accessory pathway with preexcited atrial fib-
rillation. Catheter ablation has been also used with success
in selected patients with or without structural heart disease
and with VF triggered by ventricular ectopics or Purkinje
potentials.94,95,244,249,251,255,256,258,340
Recommendations
The indications of ablation in nonischemic VT and VF
as recommended by ACC/AHA/ESC are summarized in
Table 4.21
Indications for Ablation of Ischemic VT/VF
Catheter ablation of ischemic VT/VF is not recommended
as primary or sole treatment. It is generally indicated as an
TABLE 4
Indications of Ablation for Nonischemic VT and VF
Class I:
1. Sustained monomorphic VT in patients at low risk of sudden death
when drug therapy is not effective, not tolerated, or not preferred
(level of evidence C)
2. Bundle branch reentrant VT (level of evidence C)
3. Adjunctive treatment for VT storm in patients with an ICD (level of
evidence C)
4. Accessory pathway ablation in VF caused by preexcited AF in
WPW syndrome (level of evidence B)
Class II a:
1. Symptomatic nonsustained VT in patients at low risk of sudden
death when drug therapy is not effective, not tolerated, or not
preferred (level of evidence C)
2. Frequent symptomatic PVC in patients at low risk of sudden death
when drug therapy is not effective, not tolerated, or not preferred
(level of evidence C)
3. Ablation of accessory pathway to prevent VF in symptomatic
patients with WPW syndrome in whom the refractory period of the
accessory pathway is less than 240 ms (level of evidence B)
Class II b:
1. Ablation of Purkinje fiber potentials in VT/VF storm consistently
triggered by ectopics of a similar morphology (level of evidence C)
2. Ablation of asymptomatic PVC to avoid or treat
tachycardia-induced cardiomyopathy (level of evidence C)
Class III:
1. Ablation of asymptomatic and infrequent PVC is not indicated (level
of evidence C)
AF = atrial fibrillation; PVC = premature ventricular contractions;
VF= ventricular fibrillation; VT= ventricular tachycardia; WPW=Wolff-
Parkinson-White.
adjunctive therapy in postinfarction patients with ICD who
experience frequent recurrences of ventricular arrhythmias
or electrical storm, without any apparent correctable cause
and despite adequate medical treatment. This is not a rare
event in clinical practice. Of patients who receive an ICD
for secondary prevention of SD, 40–60% experience recur-
rent episodes of VT/VF.341 Electrical storm occurs in up
to 20% of cases.342 In addition, of patients who receive
an ICD for primary prevention of SD, 20% experience at
least 1 VT episode within 3–5 years after ICD implanta-
tion.343 Catheter ablation is able to abolish VT and has a
high acute success rate in eliminating the dominant type of
VT. Accumulated evidence suggests that acute suppression
of clinical VT in electrical storm can be achieved in approxi-
mately 90% of patients.191 However, arrhythmic recurrences
are frequent during follow-up. Other indications to ablation
of VT/VF in postinfarction patients are listed in Table 5. Re-
cently, it has been reported that triggering foci originating
from the Purkinje system may be the cause of VF occur-
ring early or late after myocardial infarction. The ablation
of these foci has been proposed as life-saving procedure in
subjects with electrical storm due to VF clearly caused by
PVC.96,250
Recommendations
The indications of ablation for ischemic VT, in accordance
with the ACC/AHA/ESC 2006 guidelines for management
of patients with ventricular arrhythmias and the prevention
of SD7 are summarized in Table 5.
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TABLE 5
Indications of Ablation for Ischemic VT
Class I:
1. Patients after myocardial infarction with an ICD who present with
repetitive monomorphic VT that leads to multiple shocks or who
present with drug-refractory incessant VT or “electrical storms” that
cannot be avoided despite adequate reprogramming of the
antitachycardia pacing mode and that cannot be prevented by
beta-blocker and/or antiarrhythmic drug therapy or when patients
are intolerant of these drugs (level C)
2. Patients after myocardial infarction with an ICD who present with
repetitive sustained VT, which made mandatory the therapy with
antiarrhythmic drugs that decreased the rate of VT below an
acceptable intervention rate into the range of exercise-induced sinus
rhythm despite concomitant beta-blocker therapy (level C)
3. Patients with bundle branch reentry after myocardial infarction
(level C)
Class II a:
1. Patients after myocardial infarction with an ICD who present with
infrequent monomorphic VT that have been terminated successfully
by more than one electrical shock that most probably cannot be
avoided in the long-term future despite adequate reprogramming of
the antitachycardia pacing mode and where it is difficult to predict
whether future events can be avoided by beta-blocker and/or
antiarrhythmic drug therapy or when patients are not willing to take
long-term drugs the efficacy of which cannot be predicted
beforehand (level C)
Class II b:
1. As the sole procedure, that is, without an ICD, in patients after
myocardial infarction who have relatively well-preserved LV
function (above 35% to 40%) and in whom VT is monomorphic,
relatively slow and well tolerated, who are considered to have a
good long-term prognosis, and who are either drug resistant, do not
tolerate an antiarrhythmic drug, or do not accept long-term therapy
(level C)
2. Patients after myocardial infarction who present with frequent
self-terminating monomorphic VT that may cause shock
intervention by the ICD that potentially cannot be avoided by
changing the intervention rate of the ICD (level C).
3. Patients with markedly reduced longevity and comorbidities (e.g.,
heart failure, reduced renal function) where VT can either not be
prevented by antiarrhythmic drug therapy or drugs have not been
tolerated and where an ICD would not be indicated due to the
overall conditions of the patient
4. Patients with more than one intervention of the ICD by a shock that
is causing severe anxiety and psychological distress
ICD = implantable cardioverter defibrillator; LV = left ventricular;
VT = ventricular tachycardia.
Hybrid Therapy: Ablation and ICD
In SMASH-VT, catheter ablation reduced the incidence
of ICD therapy (shocks or antitachycardia pacing) from
33% (ICD alone) to 12% (ablation plus ICD) (P = 0.007).
Mortality was not increased in the group assigned to ab-
lation as compared with the control group (9% vs 17%,
P = 0.29). Therefore, ablation of VT/VF may be useful
to prevent arrhythmic recurrences and device intervention
in patients implanted with ICD for secondary prevention
of SD.
Recommendations
Indications of a hybrid therapy consisting of ablation and
ICD at present are:
Class II a
To reduce the burden of VT recurrences in patients receiv-
ing an ICD for secondary indication, catheter ablation may
be considered (level C).
Future Tools and Treatment Options for Catheter
Ablation of VT/VF
Image-Integration-Based Mapping
Future progress in mapping and ablation of VT/VF will
require the extension of currently available tools and tech-
nologies and the development of new approaches. It is anti-
cipated that scar delineation will be one of these increasingly
applied techniques.113 Classically, this has been based upon
voltage mapping, but it has received renewed emphasis with
the application of electroanatomic mapping. Obtaining an
accurate 3D reconstruction of the ventricles with a precise
demarcation of the scar zones is, however, time-consuming
and technically difficult.
Cardiac MRI with delayed contrast enhancement analy-
sis has emerged as the noninvasive, gold standard, diagnostic
tool to analyze the topography and transmural extent of my-
ocardial infarction.344-346 Retention of gadolinium contrast
in scar zones results in increased signal intensity on T1-
weighted images relative to that of the normal myocardium.
It is important, however, to recognize that delayed myocardial
enhancement is not specific to myocardial infarction and can
occur in a variety of other disorders, such as inflammatory
or infectious diseases of the myocardium, cardiomyopathy,
cardiac neoplasms, and congenital or genetic cardiac patho-
logic conditions. There are, however, differences in terms
of scar location as well as transmural scar extent accord-
ing to the underlying heart disease.347 As a consequence,
delayed contrast enhancement MRI may ultimately aid diag-
nosis. Finally, scar/fibrosis data on MRI have been shown to
be associated with ventricular arrhythmogenicity in different
cardiac pathologic conditions.348,349
Integration of 3D CT scan or MRI cardiac images into a
3D mapping system would be of great interest for guiding VT
ablation, as already shown for supraventricular tachycardias.
As compared with MRI scar definition, a recent study350
showed that 3D electroanatomic mapping only provides a
rough delineation of infarct areas. A clear mismatch in scar
delineation was observed on the Carto map in one-third of the
scars. Merging a preacquired MRI data set into the mapping
system could also provide a precise anatomical context and
may help identifying postinfarct VT circuits.
Future systems in general will not only facilitate the un-
derstanding of the underlying tachycardia substrate, but will
also enhance the ability to assess lesion formation during
the energy delivery in order to make the ablation itself more
efficient. This will be particularly true in the much thicker
ventricular myocardium, where assessment of the formation
of lesions during the actual ablation will be valuable. The
implementation of remote navigation systems351 will require
integration of mapping, recording, and imaging systems.
Future Tools and Treatment Options for
Epicardial VT Ablation
Safe access of the pericardial space
Accessing the pericardial space allows that extensive ar-
eas of epicardial ventricles can be explored using standard
catheters.132,134 However, there is still concern about the
safety of percutaneous pericardial puncture due to pericardial
bleeding and or ventricular perforation.132 Thus, technical
development is still needed to access the pericardial space.
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A specific device has been constructed aiming to aspirate the
parietal pericardium in order to facilitate the introduction of
a needle and a guidewire in the pericardial space.352 Maha-
patra et al.353 also recently constructed a device capable of
measuring the pressure-frequency components observed at
the needle tip during introduction. Intracardiac approaches
to accessing the pericardial space have also been proposed.
Verrier et al. first described a percutaneous approach via
the right atrial appendage.354 Since this approach was pro-
posed, no attempts for epicardial mapping and ablation have
been performed as regular sheaths and electrophysiologic
catheters are larger than used in such preliminary studies.
However, developing a system that could close and stitch
the right appendage after sheath withdrawal would add even
more safety and confidence while performing such pericar-
dial access.
Catheter ablation on the epicardial surface of the ventricles
Additional epicardial ablation development will take ad-
vantage of coronary artery or vein access. The coronary ves-
sels are natural barriers for epicardial ablation. RF pulses
delivered near an artery may result in intima hyperplasia and
thrombosis.139 On the other hand, ablation near large vessels,
with increased arterial and venous flow, might preclude my-
ocardial lesion development underneath the vessels that could
be involved in the reentrant circuit.355 Therefore, accessing
the coronary venous system should be a good alternate in
case of a perivascular VT substrate.46,356 Direct visualiza-
tion of the epicardial surface through a customized pericar-
dial endoscope might also facilitate a safer epicardial RF
delivery.357 The epicardial fat thickness is also an important
barrier to RF epicardial ablation. Cooled-tip catheters138 and
ultrasound energy create larger lesions despite the presence
of fat interposed between the catheter tip and the epicardium,
although there may persist the risk that a coronary artery
could be occluded. Thus, more investigations are needed to
safely ablate in that area. There is also an intrinsic risk for
collateral tissue injury involving the phrenic nerve, parietal
pericardium, pleural membrane, and lungs. Intrapericardial
balloons or injection of fluid and air315,316,358 have been used
to prevent phrenic nerve injury;315 however, a specific device
should be developed to facilitate access to divergent areas of
the pericardial space. Another way to prevent neighboring
structure injury is through an epicardial customized ther-
mally shielded catheter. Fenelon et al. compared lesion sizes
obtained via regular irrigation-tip electrodes and thermally
shielded electrodes in dogs. The latter thermally shielded
approach promoted the same creation of similar lesion size
as regular catheters, but prevented injury to the contiguous
tissue.359 In summary, many new strategies and tools are
under evaluation, giving expectation that epicardial and en-
docardial VT mapping and ablation might be performed in
combination with more reliable pericardial access, under di-
rect visualization, and with specific catheters and sources of
energy in the future.
Ultrasound and Laser Energy for Endocardial and
Epicardial Catheter Ablation of VT/VF
Future tools for ablating the ventricular myocardium will
undoubtedly leverage alternate energy sources. Deeper le-
sions are desirable for catheter ablation of VT, especially VT
associated with prior myocardial infarction or ARVC. Ultra-
sound and laser energy may have several advantages over RF
energy for endocardial and/or epicardial catheter ablation of
VT.
Ultrasound energy
Ultrasound energy is only minimally absorbed by blood.
Therefore, there is little or no direct heating of blood during
endocardial ablation, resulting in a lower risk of thrombus
than for RF energy.361-363 Ultrasound energy decays as the
inverse of distance from the source. In contrast, RF energy
decays as the inverse of the square of the distance. The re-
duced decay allows ultrasound energy to produce a more
homogeneous pattern of tissue heating with less focal hot
spots in the tissue, a lower risk of steam pop, and deeper
lesions (Fig. 5). Ultrasound penetration into the myocardium
is dependent on frequency (higher the frequency, less the
depth of penetration). Ablation using ultrasound at 20, 9, and
1 MHz would be expected to have a depth of active heating
of 1–2 mm, 5–6 mm, and 25–30 mm, respectively. In a pre-
liminary study, ablation using a 9 MHz ultrasound catheter
created long (>14 mm) and deep (>8 mm) lesions without
thrombus or steam pop in a canine thigh muscle prepara-
tion.362 The advantage of ultrasound energy for percutaneous
epicardial ablation is the ability to penetrate epicardial fat and
no requirement for additional external cooling. The limita-
tions for epicardial ablation are: (1) acoustic insulation may
be required to prevent collateral damage to a coronary artery
and phrenic nerve and (2) injection of saline into the peri-
cardial space may be required to ensure an air-free interface
between the catheter and the epicardium.
Laser energy
A major advantage of laser energy for ablation of VT is
the ability to use an endoscopic fiber to allow direct visu-
alization of the ablation target. Because the laser energy is
absorbed by blood, lasing into blood may produce thrombus.
This can be avoided by using a balloon filled with clear fluid,
generally D2O (heavy water), and visualizing the ablation
filed through the endoscopic fiber.363 Another advantage of
endoscopic visualization is that scar and scar border can be
easily seen for scar localization. Laser energy may not be well
absorbed by fibrous tissue. This may result in refraction of
the laser light until reaching myocardial cells for improved
ablation of surviving myocardial bundles (arrhythmogenic
channels) within the scar. The advantages of laser energy
for percutaneous epicardial ablation are: (1) penetration of
epicardial fat; (2) the ability to penetrate through air in the
pericardial space; and (3) directional focus to prevent collat-
eral damage to a coronary artery and phrenic nerve. Future
ablation using new tools, such as ultrasound and laser energy
sources, combined with new localization techniques, such as
direct visualization using endoscopy, may improve the ease,
efficacy, and safety for endocardial and epicardial catheter
ablation of VT/VF.
Virtual Electrode and Cellular Ablation
A substantial amount of progress in the development of
new energy technologies has been made over the past 10
years. This has enabled the creation of larger lesions that
may be more effective in penetrating through underlying tis-
sue abnormalities, such as infarct scar. Large and irrigation-
tip electrodes allow tissue cooling through internal flow or
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convective means, thereby fostering the delivery of higher
powers with less chance of an impedance pop or scar for-
mation. Nevertheless, these approaches remain limited in
reaching circuits embedded in thick scar. As a result, nee-
dle tip electrodes have been developed for the delivery of
both energy and higher ionic strength solutions, such as nor-
mal saline into the tissue.364,365 The combination of this de-
livery results in a synergistic effect to create a larger “vir-
tual electrode.” Recent studies364,365 have demonstrated the
utility of such a system for creating large linear lesions in
infarcted myocardium. In studies abating normal and ab-
normal infarcted myocardium, these investigators demon-
strated that up to 90% of embedded tissue strands rel-
evant for reentrant circuit in an infarct were effectively
eliminated. Additional studies demonstrated the creation
of contiguous linear lesions extending through the entire
myocardium. Sapp et al.365 have also demonstrated higher
delivery of power to within tissue, providing more full thick-
ness energy delivery than possible with standard irrigation-
tip catheters. While these data provide new insight into the
generation of larger lesions, additional efforts will be re-
quired to produce controllable lesions of narrower width.
To date, the safety of these approaches has also been un-
derstudied. Nevertheless, in normal myocardium, recent pre-
liminary studies show little effect on chamber volumes or
left ventricular function as measured in the EF. Undoubt-
edly, the application of this technology would require care-
ful targeting of infarcted areas rather than residual healthy
myocardium.
Cell Therapies
Another avenue for investigation of novel treatment
modalities is that of cell therapy for arrhythmias. Extensive
studies detail the utility of delivery of either stem cells or bone
marrow progenator cells to the enhancement of myocardial
contractility.366 The issue of whether or not these approaches
serve an antiarrhythmic purpose has been less completely
explored. Recently, Bunch et al.367 demonstrated that autol-
ogous fibroblasts cultured from the dermis of canines could
be injected into peri-AV nodal tissue to modulate conduction
during atrial fibrillation in an intact canine model. While the
effect was pronounced with cells alone, fibroblasts incubated
with TGF Beta 1 grew to a much larger extent, resulting in
greater prolongation in AV nodal conduction time, also re-
ducing the ventricular response rate during atrial fibrillation.
Others have shown similar findings in porcine models.368
These data suggest that cell injection might critically alter
conduction to reduce AV nodal transit in the setting of this
arrhythmia. It has also been hypothesized that similar cellular
injections would more homogenize the periphery of infarcts,
perhaps leading to a decrease in infarct-related ventricular
arrhythmias.369
Whether or not cellular injection might have a benefi-
cial effect on impulse formation or propagation is at present
unknown. A variety of studies have now demonstrated the
possibility of the creation of automatic tissue capable of gen-
erating sinus node-type impulses.370 The use for enhancing
conduction elsewhere in the myocardium has not been ex-
amined, but should serve as an important area of subsequent
research. While each of these areas are exciting, much addi-
tional work will be required to bring these to a level permit-
ting full application in the clinical arena.
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